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At a glance summary: 
Scientific Knowledge on the Subject: COPD macrophages have defective 
phagocytosis but the mechanism and clinical relevance remain unknown. 
What This Study Adds to the Field: COPD alveolar macrophages (AM) have a 
specific defect in opsonic phagocytosis which correlates with clinical phenotype. 
COPD AM fail to engage an anti-oxidant transcriptional module following exposure 
to opsonized bacteria. Agonists of a key transcriptional regulator of anti-oxidant host 
defense, Nrf2, reverse the opsonic phagocytosis defect in COPD and offer a potential 
therapeutic approach to correct the defect. 
 
Footnote: 
Presented in part as “COPD alveolar macrophages have a defect in opsonic 
phagocytosis of serotype 14 Streptococcus pneumoniae”. M.Bewley, R.Budd, 
D.Singh, P.J. Barnes, L.E. Donnelly, D.H.Dockrell and M.K.Whyte. American 
Thoracic Society International Conference San Diego May 18
th
, 2014. Am J. Respir 
Crit Care Med 189:2014; A1011 
 
This article has an online data supplement, which is accessible from this issue's table 
of content online at www.atsjournals.org 
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Abstract  
Rationale: Previous studies have identified defects in bacterial phagocytosis by 
alveolar macrophages (AM) in patients with chronic obstructive pulmonary disease 
(COPD) but the mechanisms and clinical consequences remain incompletely defined. 
Objectives: To examine the effect of COPD on AM phagocytic responses and 
identify the mechanisms, clinical consequences and potential for therapeutic 
manipulation of these defects. 
Methods: We isolated alveolar macrophages (AM) and monocyte-derived 
macrophages (MDM) from a cohort of COPD patients and controls within the MRC 
COPD-MAP consortium and measured phagocytosis of bacteria in relation to opsonic 
conditions and clinical features. 
Measurements and Main Results: COPD AM and MDM have impaired 
phagocytosis of S. pneumoniae. COPD AM have a selective defect in uptake of 
opsonized bacteria, despite the presence of anti-pneumococcal antibodies in 
bronchoalveolar lavage, not observed in MDM or healthy donor’s AM. AM defects in 
phagocytosis in COPD are significantly associated with exacerbation frequency, 
isolation of pathogenic bacteria and health related quality of life scores. Bacterial 
binding and initial intracellular killing of opsonized bacteria in COPD AM was not 
reduced. COPD AM have reduced transcriptional responses to opsonized bacteria, 
including cellular stress responses that include transcriptional modules involving 
antioxidant defenses and Nrf2-regualted genes. Agonists of the cytoprotective 
transcription factor Nrf2 (sulforaphane and Compound 7) reverse defects in 
phagocytosis of S. pneumoniae and non-type able Haemophilus influenzae by COPD 
AM.  
Conclusions: Patients with COPD have clinically relevant defects in opsonic 
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phagocytosis by AM, associated with impaired transcriptional responses to cellular 
stress, which are reversed by therapeutic targeting with Nrf2 agonists.  
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Introduction.  
 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung 
condition characterised by progressive airflow limitation (1, 2). COPD is associated 
with increased susceptibility to bacterial airway infection. Exacerbations cause acute 
worsening of symptoms, leading to hospitalization (3) and to disease progression (4). 
Approximately 50% of exacerbations are due to bacterial infection (5) and, in a long-
term cohort study, the lower airways were chronically colonized with Streptococcus 
pneumoniae in a third of patients (6). Individuals living with COPD are also at 
increased risk of community-acquired pneumonia (CAP) with increased mortality, 
most often caused by S. pneumoniae (7). This suggests COPD leads to an innate 
immune defect against S. pneumoniae and other bacteria. 
 
Alveolar macrophages (AM) are the resident phagocytes enabling bacterial clearance 
from the lung, but COPD AM demonstrate reduced phagocytosis of Haemophilus 
influenzae and P. aeruginosa (8, 9), while COPD monocyte-derived macrophages 
(MDM) show impaired phagocytosis of S. pneumoniae (10). Bacterial phagocytosis 
by macrophages involves both non-opsonic and opsonic pathways (11, 12). Previous 
studies of COPD macrophages have examined non-opsonic or complement-mediated 
phagocytosis but phagocytosis in the presence of opsonizing antibody has not been 
studied in detail. A specific defect in opsonic phagocytosis would be particularly 
relevant to capsulated micro-organisms, such as S. pneumoniae, which require 
opsonization for efficient phagocytosis (13), involving both IgG and complement 
present in alveolar fluid (14).  
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We investigated mechanisms underlying phagocytic defects in the COPD lung. COPD 
Opsonization fails to enhance AM phagocytosis, although it enhances MDM 
phagocytosis. The level of AM opsonic phagocytosis was strongly associated with 
clinical and microbiological phenotype. AM responses to opsonized S. pneumoniae 
activated cellular stress transcriptional responses to antioxidant responses, but these 
were abrogated in COPD AM. Agonists of the antioxidant transcription factor, 
nuclear factor (erythroid-derived2) like 2 (NFE2L2) or Nrf2, a prominent component 
of antioxidant transcriptional responses, corrected the defect in AM opsonic 
phagocytosis in COPD. Some of the results of these studies have been previously 
reported in the form of an abstract (15). 
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Methods 
Macrophage donors: COPD patients, free from exacerbation, were recruited from the 
UK Medical Research Council (MRC) COPD-MAP consortium with written 
approved consent, as outlined online.  
 
Cells and Infection: AM were isolated from broncho-alveolar lavage (BAL) as 
previously described (13). Cells were >95% AM as assessed by Diff-Quick staining 
(Dade Behring) visualised by light microscopy (Leica DMRB 1000). Human MDM 
were differentiated for 14 d from peripheral blood mononuclear cells isolated from 
donors with written informed consent by Percoll (Sigma) gradient. Cells were 
cultured in RPMI (Lonza) supplemented with 10% FCS with low LPS (Lonza). Some 
cells were incubated with 10 µM of sulforaphane, 0.065 µM Compound 7, a selective 
inhibitor of the Kelch-like ECH-associated protein 1 (KEAP1) /Nrf-2 interaction 
(16),  or vehicle control for 16 h before challenge with bacteria. 
 
Bacteria: Serotype 14 S. pneumoniae (NCTC11902) represents a serotype commonly 
causing infection in COPD (17). Stocks were grown as previously described (18). 
Non-typeable H. influenzae (NCTC 1269) was cultured as outlined in the online 
supplement. Macrophages were infected at a multiplicity of infection (MOI) of 10:1. 
S. pneumoniae were opsonized for 15 min. with immune serum obtained from 
volunteers vaccinated with pneumococcal polysaccharide vaccine, and with detectable 
antibody levels against S. pneumoniae, prior to macrophage challenge (13). Viable 
intracellular bacteria were measured at 4 h post-challenge as a measure of bacterial 
internalization using a gentamicin protection assay (GPA) as previously described 
(19). For assessment of early S. pneumoniae killing, macrophages were challenged for 
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4 h before GPA, while additional wells were placed in media containing 0.75 µg/ml 
vancomycin before GPA at the designated time points. 
 
Bacterial binding: Bacterial binding and internalisation were assessed by fluorescence 
microscopy (Leica DMRB 1000) (13). Detailed information can be found in the 
online supplement.   
 
Cell surface marker expression.  Cell surface marker expression was measured by 
flow cytometry, as described online.  
 
Transcriptomic analysis: RNA was extracted and hybridized onto the Affymetrix HG-
U133 plus 2.0 Array. Data were analysed in R using affyPML and Limma. 
Enrichment analysis of Gene Ontology (GO) terms using a Hypergeometric model 
using GOstats package in R was performed for differentially expressed genes. False 
discovery rates (FDR) were corrected with the Benjamini-Hochberg procedure. More 
detailed information is included in the online supplement. 
  
Western blot: Whole cell extracts were isolated using SDS-lysis buffer and separated 
by SDS gel electrophoresis, as described in the online supplement.  
 
Statistics: Results are recorded as mean and SEM.  Sample sizes were informed by 
standard errors obtained from similar assays in prior publications  (13, 18). Decisions 
on use of parametric or non-parametric tests were based upon results of  D'Agostino-
Pearson normality tests.   Comparisons were made by paired student t-test and 
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Significance was defined as P < 0.05. 
Results 
Demographic data for macrophage donors. 
The demographic features for the COPD-MAP macrophage donors are listed in Table 
1. The COPD patients had a significantly greater number of pack years of cigarette
exposure. Sixteen of 42 COPD patients (38.1%) had a history of frequent 
exacerbations (≥2/year). Vaccine history was available in 69% and of these 83% of 
COPD patients had received a pneumococcal vaccine. 
COPD AM have selective defects in phagocytosis of opsonized S. pneumoniae. 
Both COPD AM and MDM demonstrated reduced intracellular numbers of S. 
pneumoniae compared to healthy controls, irrespective of opsonic conditions (Figure 
1A-D). COPD AM (but not MDM) from frequent exacerbators had reduced 
intracellular bacteria, irrespective of opsonic conditions (Figure 1A-D). Frequent 
exacerbation was set at ≥2 exacerbations/yr. and as shown in Figure E1 patients with 
only one exacerbation did not have a reduction in bacteria uptake, while those with ≥2 
did. Paired analysis of intracellular bacteria numbers, comparing MDM with AM 
from the same donor, showed that intracellular S. pneumoniae were lower in AM than 
MDM in COPD (but not healthy groups,) regardless of opsonic condition or 
exacerbation frequency (Figure 1E-F). Opsonization significantly increased numbers 
of intracellular bacteria in all MDM groups, but significantly increased numbers only 
in healthy, not COPD, AM (Figure 1G-H). 
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The number of viable intracellular S. pneumoniae is influenced by both phagocytosis 
and the rate of early intracellular killing (13). To establish that lower intracellular 
viable bacteria in COPD AM were not due to alterations in bactericidal activity, we 
measured the kinetics of intracellular killing. Opsonization did not alter the rate of 
bacterial killing in any macrophages (Figure E2A-D). Opsonization appropriately 
increased both the percentage of healthy AM binding bacteria, and also the 
number of internalized bacteria binding per macrophage but did not enhance 
uptake in COPD (Figure E3). Binding of non-opsonized or opsonized S. pneumoniae 
was not altered by COPD or exacerbation frequency. Surface expression of Fcγ 
receptors, CD16, CD32 and CD64 were similar in AM/MDM of COPD patients and 
controls (Figure E4A-B). Studies have demonstrated a central role for the Exchange 
protein activated by cAMP 1 (Epac-1) in the inhibition of Fc-γ receptor-mediated 
phagocytosis (20). However, AM expression of Epac-1, or of its primary target Rap-1 
(21) was unaltered by S. pneumoniae challenge or by COPD (Figure E4C-D).  
Similarly, there was no difference in expression of Rac1, a Rho-family GTP-
binding protein that regulates lamellipodia formation and membrane ruffling in Fc 
receptor-mediated phagocytosis in AM (22).  
 
Since COPD AM demonstrate a specific defect in opsonic phagocytosis we confirmed 
if patient bronchoalveolar lavage fluid (BAL) samples had significant levels of anti-
pneumococcal antibodies. We measured antibodies against the 13 serotypes included 
in Prevnar-13, a licensed protein conjugate vaccine, using a sensitive multiplex 
immunoassay. Unconcentrated BAL samples had detectable pneumococcal antibodies 
to 2.9 ± 0.5 serotypes and 72% of samples had antibody against at least one serotype, 
with a range of 0-9 serotypes. Antibodies were most common to serotypes 3 (38%), 
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serotype 14 (45%) and serotype 19A (45%), see Figure E5. More specifically for the 
COPD sample 73% had detectable antibodies to 1 or more serotypes. 
 
Decreased opsonic phagocytosis in COPD is associated with bacterial 
colonisation and correlates with clinical features. 
COPD lungs are often colonized with bacteria, most often H. influenzae and S. 
pneumoniae (23), and colonization is associated with increased exacerbation 
frequency (6). Since AM are essential mediators of pulmonary innate immunity (24),  
we established whether AM phagocytic defects were associated with bacterial 
colonization. We found that COPD patients who were culture-positive for pathogenic 
micro-organisms (PPMs) in their sputum had significantly lower levels of AM 
phagocytosis for opsonized, but not non-opsonized S. pneumoniae, when compared to 
culture-negative patients (Figure 2A-B). In contrast, using qPCR to identify 
pathogenic micro-organisms in BAL, we determined that PCR-positive samples were 
not associated with lower levels of opsonic or non-opsonic AM phagocytosis of S. 
pneumoniae (Figure 2C-D).  
 
Correlation analysis of non-opsonized and opsonized phagocytosis of S. pneumoniae 
against FEV1 showed that there was a significant relationship between FEV1 and 
levels of opsonic phagocytosis, but not non-opsonic phagocytosis (Figure 3A-B). 
However, since FEV1 correlates poorly with symptoms in COPD (25), we also looked 
to see if AM phagocytosis levels were related to scores from health-related quality of 
life (HR-QoL) instruments, the St George's Respiratory Questionnaire (SGRQ), 
COPD Assessment Test (CAT) or with the 6-minute walking distance (6MW). For the 
SGRQ and CAT score (although not for the 6MW), there was a significant correlation 
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between impaired opsonic phagocytosis and scores representative of increased 
symptom severity but, in contrast, non-opsonic uptake was not correlated with any 
HR-QoL score, suggesting it was less tightly associated with COPD symptoms 
(Figure 4A-F).  
COPD AM have reduced transcription of antioxidant genes induced in response to 
opsonized bacteria. 
To provide further insights into the mechanisms influencing the selective defect in 
opsonic phagocytosis in AM we next looked at the transcriptional response of AM 
to opsonized S. pneumoniae. There are significantly fewer differentially expressed 
genes in the COPD AM in response to infection than in healthy AM (Figure 5A). 
Table E1-2 shows the top ten upregulated and downregulated gene probes in 
healthy and COPD AM respectively. We reviewed the enriched GO terms and 
noted fewer terms differentially regulated in COPD and lower levels of induction 
(Figure 5B).  We also observed that, within the Biological Processes differentially 
regulated, although the GO term relating to the cellular response to stress was 
prominently enriched in healthy AM, it comprised significantly fewer components 
in the COPD AM (supplemental Table E3). Included in this response are a series 
of genes regulating antioxidant defense, which were prominent in the genes altered 
in healthy AM (Figure 5C, supplemental Figure E6 and supplemental Table E4), 
but these showed comparatively less differential regulation in in COPD.   
Although these responses are not recognized as a major feature of innate host 
responses to bacteria, antioxidant responses modulate inflammatory responses. 
These antioxidant responses are activated by a variety of sources of oxidative 
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stress including microbicidal responses to bacteria and baseline reductions in 
antioxidant responses  are previously described in COPD (26).  
 
Activation of Nrf2 increases phagocytosis of non-opsonized and opsonized S. 
pneumoniae in AM but not MDM. 
Increased oxidative stress in the COPD lung has been associated with impairment 
of phagocytosis of non-opsonized unencapsulated bacteria and apoptotic bodies 
(27, 28). The transcription factor Nrf2 is a key regulator of cytoprotective proteins 
including antioxidants (29, 30) and treatment of macrophages with a pharmacological 
activator of Nrf2, sulforaphane, increases phagocytosis of non-type able H. influenzae 
(NTHi) and Pseudomonas aeruginosa in COPD AM (8). Within the differentially 
expressed genes in AM following pneumococcal challenge, we identified multiple 
Nrf2 regulated genes in healthy AM, but these were not differentially regulated in 
COPD AM (Figure 5C and supplemental Table E5).  
 
Since we identified impairment of an antioxidant transcriptional module we next 
tested whether sulforaphane modulated phagocytosis of S. pneumoniae. We 
confirmed sulforaphane activated heme-oxygenase (HO-1), an Nrf-2 target gene, in 
COPD macrophages (Figure 6A-B) and did not induce either apoptosis or necrosis 
in macrophages (Figure E7). Sulforaphane significantly increased numbers of 
intracellular bacteria after challenge with non-opsonized S. pneumoniae in both 
healthy and COPD AM (Figure 6C), but after challenge with opsonized S. 
pneumoniae only in COPD (not healthy) AM (Figure 6D). In contrast, we failed to 
demonstrate an uplift in MDM ingestion under any of the conditions studied 
(Figure 6E-F). To determine if this pattern occurred with other bacteria, we 
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confirmed sulforaphane also increased intracellular numbers of NTHi in COPD 
AM but not healthy AM/MDM or COPD MDM (Figure 6G-H). We also confirmed 
sulforaphane did not alter the rate of early intracellular killing of S. pneumoniae in 
COPD AM (Figure 6I). Moreover, sulforaphane did not significantly induce 
expression of Fc-gamma expression (CD16, 32 or 64) in either AM or MDM 
(Figure E8). To determine if the uplift in phagocytosis was sulforaphane specific, 
cells were also treated with a more specific Nrf2 agonist, Compound 7. This is a 
recently described potent and selective inhibitor of the Kelch-like ECH-associated 
protein 1 (KEAP1) /Nrf-2 protein-protein interaction (16). Treatment with 
Compound 7, also induced expression of HO-1 in COPD MDM in a 
concentration-dependent manner (Figure 7A) and importantly glutamate-cysteine 
ligase catalytic subunit (GCLC) and NADPH:quinone oxidoreductase 1 (NQO1), two 
of the Nrf2-regulated tragets upregulated by infection,in AM (Figure 7B). 
Compound 7 significantly increased phagocytosis of opsonized and non-opsonized 
S. pneumoniae by COPD (but not helathy) AM and MDM (Figure 7C-F). As with 
sulforaphane Compound 7 treatment did not induce cytotoxic effects (Figure 
E7B). To complete the data set with compound 7 (and for healthy donors in Figure 
6G) we added some additional patients recuited outside COPD-MAP, whose 
demographics are shown in Table E6. These findings illustrate the potential to 
reverse opsonic phagocytic defects with Nrf2 agonists. 
 
Discussion 
We have demonstrated that COPD macrophages have reduced phagocytosis of 
bacteria. Although we observed defects in MDM phagocytic function, failure to 
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induce phagocytic uplift by opsonization was unique to COPD AM and was the 
specific defect that was most predictive of clinical phenotype. COPD AM exposed to 
opsonized bacteria had decreased transcriptional responses involving antioxidant 
defenses. Importantly AM defects in bacterial uptake were reversed with Nrf2 
agonists.  
 
Several prior publications have demonstrated COPD is associated with impaired 
macrophage phagocytosis of bacteria and apoptotic cells (8, 9, 10, 31). These studies 
suggest that there is both a local AM defect but also a systemic defect in macrophage 
function, which may arise from a combination of genetic, epigenetic and 
environmental factors. Our study extends our understanding by showing an additional 
select defect in AM function that inhibits phagocytosis of opsonized bacteria. 
 
Both complement and immunoglobulin are present in alveolar lining fluid (14). 
Pneumococcal-specific IgG is detected in human BAL (32) and is required for 
optimal phagocytosis of S. pneumoniae by AM (13). Our study also confirms the 
presence of anti-pneumococcal antibodies in unconcentrated BAL, in a COPD 
population, in which available data showed >80% vaccination uptake, and an age 
matched population some of whom would have had vaccine on the basis of age. 
Therefore, a defect in opsonic uptake could reduce the efficacy of vaccination despite 
the presence of pneumococcal antibodies in the airway. In a murine model cigarette 
smoke reduced complement-mediated S. pneumoniae uptake, but not phagocytosis of 
IgG coated beads (33). Impaired phagocytosis of opsonized S. pneumoniae and other 
encapsulated bacteria is likely to contribute to COPD pathogenesis. S. pneumoniae 
remains a leading cause of exacerbations in COPD (5) and in one study monoculture 
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of S. pneumoniae proved a specific risk factor for exacerbation (17). S. pneumoniae 
also have indirect effects on exacerbations since they promote growth, biofilm 
formation and synergy in inflammatory responses with other bacteria causing 
exacerbations (34-36). In addition, S. pneumoniae is the major cause of CAP in these 
patients (37), and COPD increases the susceptibility and risk of complications with 
CAP (7). 
Recent observations involving polymeric immunoglobulin receptor deficient mice 
illustrate how bacterial persistence drives inflammation and small airway remodelling 
in a model of COPD (38). Bacterial colonization of the airways is linked to decline in 
lung function (6, 39) and recently, bacterial phagocytosis has been shown to correlate 
with FEV1 in both COPD (40) and severe asthma (41). Reduced phagocytosis of 
opsonized bacteria by AM was observed in patients who were culture-positive, 
although PCR-positivity in BAL was not associated with the level of phagocytosis. It 
would be of interest in the future to determine if opsonic phagocytosis correlates with 
quantitation of PCR but our numbers did not allow this analysis. We used a threshold 
of >10
4
 copies/ml to define positivity. Although this threshold ensures sensitivity and
a high negative predictive value in studies on the detection of lower respiratory tract 
infection due to organisms such as S. pneumoniae and H. influenzae (42, 43) it may 
under estimate colonization. On the other hand, the detection of colonization by PCR 
with lower level PCR thresholds is problematic and diagnostic accuracy may be 
influenced by increasing numbers of false positive results. Therefore, the sputum 
detection may have been more predictive of colonization status. The defect in AM 
phagocytosis of opsonized bacteria was more severe in COPD patients with frequent 
exacerbations, a factor associated with more rapid decline in FEV1 (44). This could 
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explain the correlations we observed with more significant impairment of opsonic 
phagocytosis observed in patients with lower FEV1 or more severe symptoms with 
quality of life assessments. Assessment scales are widely used to describe COPD 
patient cohorts and stratify them for interventions, such as pulmonary rehabilitation 
(45) and to predict survival (46). Quality of life scales are complementary to FEV1 in 
describing disability (e.g. MRC dyspnea scale) or severity of dyspnea symptoms (e.g. 
COPD assessment test) in patients living with COPD and it was noteworthy that the 
SGRQ and CAT correlated with the defect for phagocytosis of opsonized bacteria. 
FEV1 provides a measure of COPD stage, but correlates poorly with symptoms (25). 
This implies the phagocytic defect may be related both to stage and symptoms.  
 
Future studies will need to identify if the phagocytic defect for opsonized bacteria is 
related to a specific receptor pathway or cytoskeletal re-arrangement. A prior study 
identified a defect in macrophage receptor with collagenous structure (MARCO) 
mediated phagocytosis in COPD (8). This important study identified impaired 
phagocytosis of two non-opsonized bacteria (NTHi and P. aeruginosa) in COPD AM 
and mice exposed to cigarette smoke and showed that sulforaphane corrected the 
defect in an Nrf2-dependent mechanism via enhanced MARCO expression. Our study 
in a population with very few current smokers is consistent with these findings 
confirming a defect in phagocytosis of non-opsonized bacteria (S. pneumoniae and 
NTHi), which is improved by Nrf2 agonists. We extend beyond this showing an 
additional defect for opsonized S. pneumoniae. In contrast to the study by Harvey and 
colleagues our study highlighted transcriptional changes associated with infection in 
healthy and COPD AM rather than the transcriptional effects of sulforaphane, but also 
highlights reductions in Nrf2-mediated responses in COPD AM.  The range of 
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particles, including both opsonized and non-opsonized bacteria and apoptotic bodies, 
for which defects have been identified in COPD, argues against involvement of any 
single receptor system underlying all these defects. Although MARCO likely 
contributes to defects in uptake of non-opsonized bacteria (8), it would not be 
anticipated to explain the impairment of opsonized bacteria by AM. An unbiased 
approach is more likely to identify mechanisms underpinning the broad systemic 
defect in phagocytosis and the more localized pulmonary defect for opsonized 
bacteria.  
 
The transcriptional responses seen in the healthy AM, in response to S. pneumoniae 
included prominent transcriptional responses involving immunometabolism. The 
acute responses to bacteria results in a shift to increased glucose uptake and glycolytic 
metabolism (47), while glucose diversion via the pentose phosphate pathway is a 
well-recognized mechanism of oxidative stress resistance (48). Amongst differentially 
expressed metabolic genes increased in healthy but not COPD AM was sirtuin (silent 
mating type information regulation 2 homologs) 1, a deacetylase involved in host 
responses to M. tuberculosis (49).  Anti-oxidant responses were prominently 
upregulated in healthy AM after bacterial infection. Nrf2 regulated genes included 
GCLC, glutathione-S-transferase zeta 1 (GSTZ-1), glutathione peroxidase 7 (GPX7) 
and the SLC7A11 gene product, light chain subunit of the Xc
-
 (xCT) 
glutamine/cysteine antiporter required, all involved in glutathione maintenance and 
utilization, carbonyl reductase 1 (CBR1), NQO1, and thioredoxin 2 (TXN2) 
detoxifying oxidoreductase enzymes and superoxide dismutase (SOD) 1 (48).  Foxo-
regulated targets including SOD 2 were upregulated, while p53 was also upregulated. 
Of all these anti-oxidant responses only p53 was significantly upregulated in COPD 
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AM after bacterial challenge. We identified upregulation of a series of genes involved 
in regulation of ubiquitination (including ubiquitin conjugating E2 enzymes B, D3 
and N), a process controlling signaling via pattern recognition receptors, in healthy 
AM after bacterial challenge (50).  Collectively these anti-oxidant responses have the 
potential to alter cytokine-induced activation of specific phagocytic pathways, 
expression of receptors or molecules involved in signaling cascades associated with 
receptors or the susceptibility of the cytoskeleton to re-arrangements altered by 
oxidative stress required for particular phagocytic pathways. It was noteworthy that 
the transcriptional response in healthy AM involved downregulation of the class B 
scavenger receptor CD36, a receptor for unopsonized particles (51) , which was not 
observed in COPD AM. 
 
The Nrf2 transcription factor regulates a cluster of antioxidant, cytoprotective and 
detoxifying genes and influences susceptibility to COPD in murine models involving 
cigarette smoke exposure by modifying inflammation and tissue injury (52). We 
confirmed prior observations suggesting Nrf2 agonists correct the phagocytic defect 
in COPD (8), but extend these by showing they also modulate phagocytosis of 
opsonized bacteria. Since this also influenced uptake of non-opsonized particles it is 
likely Nrf2 agonists have pleiotropic effects in the modulation of phagocytosis. Nrf2 
agonists represent a promising class of agents with which to modulate oxidative stress 
in conditions like COPD, particularly with the development of highly-selective agents 
that bind to the Kelch domain of KEAP1 and prevent Nrf2 ubiquitination and 
proteasomal degradation (16). While sulforaphane activates Nrf2 by targeting 
cysteine residues in the BTB domain of KEAP1 and can potentially interact with 
other targets (53) we demonstrate significant enhancement of phagocytosis in COPD 
Page 19 of 88
19
macrophages with the selective Nrf2 agonist Compound 7, suggesting this could 
represent a potent pharmacological approach with which to correct the COPD 
associated defects in phagocytosis. 
In conclusion we have identified that, although COPD induces a systemic defect in a 
range of forms of phagocytosis, a specific defect in phagocytosis of opsonized 
bacteria is observed specifically in AM and correlates closely with clinical phenotype 
in COPD. Moreover, this defect is amenable to therapeutic targeting with novel and 
selective inhibitors of the KEAP1/Nrf2 protein-protein interaction. 
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Figure Legends 
Figure 1. COPD AM show deficient opsonic bacterial phagocytosis which 
correlates with exacerbation frequency. (A-D) Alveolar macrophages (AM) (A 
and B) or monocyte-derived macrophages (MDM) (C and D) from healthy (H) or 
COPD (non-frequent (NF) and frequent (F) exacerbators) were challenged with either 
non-opsonized (A and C) or opsonized (B and D) serotype 14 S. pneumoniae. 4h post-
challenge viable intracellular bacteria were assessed. Values for ‘n=’ for H/COPD-
NF/COPD-F; (A) 18/27/15, (B) 10/19/13, (C) 14/18/12, (D) 14/15/12, ***= p<0.001, 
1-way ANOVA. (E-F) A pairwise comparison of phagocytosis of non-opsonized (E) 
and opsonized (F) bacteria in MDM and AM from matched donors, ns= not 
significant, values for ‘n=’ for H/COPD-NF/COPD-F; (E) 11/12/12, (F) 10/11/12, 
*=p<0.05, **=p<0.01, ***=p<0.001, paired t-test. (G-H) A pairwise comparison of 
phagocytosis of non-opsonized and opsonized S. pneumoniae in matched AM (G) or 
MDM (H) donors, values for ‘n=’ for H/COPD-NF/COPD-F; (G) 10/20/11, (H) 7/8/5, 
*=p<0.05, paired t-test. 
Figure 2. Defects in phagocytosis in COPD AM are associated with bacterial 
colonisation in the lung. (A-D) Non-opsonic (A and C) and opsonic (B and D) 
phagocytosis was stratified into groups dependent on if the donor had negative (-ve) 
or positive (+ve) culture of sputum (A and B, n=15 and n=14) or –ve or +ve (defined 
as >10
4
 copies/ml) qPCR of broncho-alveolar lavage (C and D, n=27 and n=26)
results indicative of bacterial colonisation, *=p<0.05, Student’s t-test. 
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Figure 3. Opsonic phagocytosis correlates with FEV1. Non-opsonic (A) and 
opsonic (B) phagocytosis rates were correlated against patient FEV1 score. Pearson’s 
correlation coefficients (r), and p values, with correlation deemed significant if 
p<0.05. n = 36 non-opsonic, 32 opsonic.  
 
Figure 4. Opsonic phagocytosis correlates with markers of COPD disease 
severity. Non-opsonic (A, C and E) and opsonic (B, D and F) rates of phagocytosis 
were correlated against patients scores in a variety of markers for COPD disease 
severity, the St George's Respiratory Questionnaire (SGRQ) (A and B) (n = 29 non-
opsonic, 27 opsonic), COPD Assessment Test (CAT) (C and D) (n = 34 non-opsonic, 
30 opsonic) or with the 6-minute walking distance (6MW) (E and F) (n = 14 non-
opsonic, 10 opsonic). Values for Pearson’s (r) or Spearman’s correlation coefficients 
(rho) and p values are shown, with correlation deemed significant if p= <0.05. 
 
Figure 5. Transcriptional response of AM reveals less differential gene 
expression in COPD in response to infection.  Alveolar macrophages (AM) from 
Healthy or COPD patients were challenged with opsonized serotype 14 S. 
pneumoniae (n=3 in each group). 4h post-challenge cell total RNA was collected for 
transcriptional analysis. (A) Venn diagram showing the number of probes 
differentially expressed in response to infection (moderated t test <0.05, FDR <0.05). 
(B) Plots represent the top ten enriched GO biological processes terms and the cellular 
response to stress term (in addition the response to oxidative stress term is plotted in 
the Healthy AM). The X axis represents enrichment by a hypergeometric test  (–log10 
(p value)). The size of the circle and colour represents the number of differentially 
expressed genes in that term. Figures generated using NIPA (available 
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at https://github.com/ADAC-UoN/NIPA). (C) Volcano plots represent the probe sets 
identified from the transcriptomic analysis. Panel a) Healthy: The red triangles are the 
differentially expressed probes related to the “Cellular response to stress term” with 
some representative terms named. In blue are the terms associated with the Nrf-2 
pathway in the analysis of healthy AM. Panel b) COPD: The red triangles are the 
differentially expressed probes related to the “Cellular response to stress” GO term. In 
blue are the terms associated with NRF2 pathway seen in the Healthy analysis. 
Figure 6. Treatment with the Nrf-2 agonist sulforaphane increases non-opsonic 
and opsonic phagocytosis in COPD AM but not MDM. (A-B) Alveolar 
macrophages (AM) and monocyte derived macrophages (MDM)(B) were pre-treated 
with the designated dose of sulforaphane (Sulf) for 16h, before cells were lysed and 
probed for expression of heme-oxygenase-1 (HO-1) and actin (n=3). (C-F) AM (C-D) 
or MDM (E and F) from healthy (H) or COPD non-frequent (NF) or frequent (F) 
exacerbators were pre-treated with vehicle (Sulf -) or Sulforaphane (Sulf +) for 16 h, 
before cells were challenged with non-opsonized (C and E) or opsonized (D and F) 
serotype 14 S. pneumoniae. 4h post-challenge, numbers of intracellular viable bacteria 
were measured, values for ‘n=’ for H/COPD-NF/COPD-F; (C) 11/19/14, (D) 8/ 10/4, 
(E) 9/9/5, (F) 8/9/5, *=p<0.05, paired t-test. (G and H) AM (G) and MDM (H) from 
COPD patients or healthy (H) donors were pre-treated with sulforaphane before being 
challenged with non-typeable H. influenzae (NTHi). 4h post challenge the numbers of 
intracellular viable bacteria were measured, values for ‘n=’ for H/COPD (G)3/4, (H) 
3/3, *=p<0.05, paired t-test. (I) COPD AM were pre-treated with sulforaphane (+Sulf) 
before being challenged with non-opsonized serotype 14 S. pneumoniae for 4h before 
extracellular bacteria were killed by the addition of antibiotics. At the designated time 
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post-antibiotics, viable bacteria in duplicate wells were measured to, n=3, no 
significant difference between vehicle and sulf. 
Figure 7. The Nrf-2 agonist compound 7 also increases phagocytosis in COPD 
AM. 
(A and B) COPD monocyte-derived macrophages (MDM) (A), or alveolar 
macrophages (AM) (B), were pre-treated with the Nrf-2 agonist Compound 7 for 16h 
at the designated dose, before cells were lysed and a probed for the expression of 
heme-oxygenase-1 (HO-1), glutamate-cysteine ligase catalytic subunit (GCLC) or 
NADPH:quinone oxidoreductase 1 (NQO1)  by western blot. (C and D) Healthy 
donor and COPD AM were pre-treated with Compound 7 at 5x IC50 (0.065 µM), for 
16h before being challenged with opsonized (C), n=3 healthy, n=5 COPD or non-
opsonized (D), n=3 healthy, n=10 COPD, serotype 14 S. pneumoniae for 4h, after 
which numbers of intracellular viable bacteria were assessed, **=p<0.01, paired t-test. 
(E and F) Healthy donor and COPD MDM were pre-treated with compound 7 and 
challenged with opsonized (E), or non-opsonized (F), S. pneumoniae as for AM. All 
n=4, p **=p<0.01, paired t-test. 
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Table 1: Demographics of Macrophage Donors 
Healthy Non-Smoker Healthy Ex-Smoker COPD 
N 12 6 42 
Age (years)  56 (43-65)  58 (48-69) 66(53-77) 
Gender 6♀ : 6♂ 2♀ : 4♂ 7♀ : 35♂ 
FEV1 Litres 3.19 (2.25-4.77) 2.99 (2.50-3.70) 1.88 (1.00-2.72) 
FEV1 % 110 (74-127) 108 (84-121) 50.8 (32-67) 
FVC litres 3.76 (2.25-5.6) 4.19 (3.45-5.2) 3.49 (1.86-5.24) 
GOLD Stage * N/A N/A 9 GOLD A 
14 GOLD B 
4 GOLD C 
10 GOLD D 
Non-Frequent 
/Frequent** 
N/A N/A NF 26 (0 Exacerbations 
= 19, 1 Exacerbation = 7 
 F 16 (2 Exacerbations 
=3, 3 Exacerbations =7, 
>3 Exacerbations =6) 
Pack Years  N/A  18 (10-35) 50 (32-67) 
Smoking Status: 
Current/Ex/Never 
0/0/12  0/6/0 7/35/0 
Inhaled 
Corticosteroids use 
0 0  35 
Vaccine N/A N/A 24 Yes, 5 No, 13N/A 
St George's 
Respiratory 
Questionnaire 
(SGRQ) Total score 
N/A N/A 39.8 (6-83) 
COPD Assessment 
Test (CAT) 
N/A N/A 16.3 (4-33) 
6 Minute Walk (m) N/A N/A 400 (264-496) 
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Figure 1. COPD AM show deficient opsonic bacterial phagocytosis which correlates with exacerbation 
frequency. (A-D) Alveolar macrophages (AM) (A and B) or monocyte-derived macrophages (MDM) (C and D) 
from healthy (H) or COPD (non-frequent (NF) and frequent (F) exacerbators) were challenged with either 
non-opsonized (A and C) or opsonized (B and D) serotype 14 S. pneumoniae. 4h post-challenge viable 
intracellular bacteria were assessed. Values for 'n=' for H/COPD-NF/COPD-F; (A) 18/27/15, (B) 10/19/13, 
(C) 14/18/12, (D) 14/15/12, ***= p<0.001, 1-way ANOVA. (E-F) A pairwise comparison of phagocytosis of 
non-opsonized (E) and opsonized (F) bacteria in MDM and AM from matched donors, ns= not significant, 
values for 'n=' for H/COPD-NF/COPD-F; (E) 11/12/12, (F) 10/11/12, *=p<0.05, **=p<0.01, ***=p<0.001, 
paired t-test. (G-H) A pairwise comparison of phagocytosis of non-opsonized and opsonized S. pneumoniae 
in matched AM (G) or MDM (H) donors, values for 'n=' for H/COPD-NF/COPD-F; (G) 10/20/11, (H) 7/8/5, 
*=p<0.05, paired t-test.  
277x418mm (300 x 300 DPI) 
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Figure 2. Defects in phagocytosis in COPD AM are associated with bacterial colonisation in the lung. (A-D) 
Non-opsonic (A and C) and opsonic (B and D) phagocytosis was stratified into groups dependent on if the 
donor had negative (-ve) or positive (+ve) culture of sputum (A and B, n=15 and n=14) or -ve or +ve 
(defined as >104 copies/ml) qPCR of broncho-alveolar lavage (C and D, n=27 and n=26) results indicative 
of bacterial colonisation, *=p<0.05, Student's t-test.  
96x47mm (300 x 300 DPI) 
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Figure 3. Opsonic phagocytosis correlates with FEV1. Non-opsonic (A) and opsonic (B) phagocytosis rates 
were correlated against patient FEV1 score. Pearson's correlation coefficients (r), and p values, with 
correlation deemed significant if p<0.05. n = 36 non-opsonic, 32 opsonic.  
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Figure 4. Opsonic phagocytosis correlates with markers of COPD disease severity. Non-opsonic (A, C and E) 
and opsonic (B, D and F) rates of phagocytosis were correlated against patients scores in a variety of 
markers for COPD disease severity, the St George's Respiratory Questionnaire (SGRQ) (A and B) (n = 29 
non-opsonic, 27 opsonic), COPD Assessment Test (CAT) (C and D) (n = 34 non-opsonic, 30 opsonic) or with 
the 6-minute walking distance (6MW) (E and F) (n = 14 non-opsonic, 10 opsonic). Values for Pearson's (r) 
or Spearman's correlation coefficients (rho) and p values are shown, with correlation deemed significant if 
p= <0.05.  
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Figure 5. Transcriptional response of AM reveals less differential gene expression in COPD in response to 
infection.  Alveolar macrophages (AM) from Healthy or COPD patients were challenged with opsonized 
serotype 14 S. pneumoniae (n=3 in each group). 4h post-challenge cell total RNA was collected for 
transcriptional analysis. (A) Venn diagram showing the number of probes differentially expressed in 
response to infection (moderated t test <0.05, FDR <0.05). (B) Plots represent the top ten enriched GO 
biological processes terms and the cellular response to stress term (in addition the response to oxidative 
stress term is plotted in the Healthy AM). The X axis represents enrichment by a hypergeometric test  (-
log10 (p value)). The size of the circle and colour represents the number of differentially expressed genes in 
that term. Figures generated using NIPA (available at https://github.com/ADAC-UoN/NIPA). (C) Volcano 
plots represent the probe sets identified from the transcriptomic analysis. Panel a) Healthy: The red 
triangles are the differentially expressed probes related to the "Cellular response to stress term" with some 
representative terms named. In blue are the terms associated with the Nrf-2 pathway in the analysis of 
healthy AM. Panel b) COPD: The red triangles are the differentially expressed probes related to the "Cellular 
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response to stress" GO term. In blue are the terms associated with NRF2 pathway seen in the Healthy 
analysis.  
285x390mm (300 x 300 DPI)  
Figure 6. Treatment with the Nrf-2 agonist sulforaphane increases non-opsonic and opsonic phagocytosis in 
COPD AM but not MDM. (A-B) Alveolar macrophages (AM) and monocyte derived macrophages (MDM)(B) 
were pre-treated with the designated dose of sulforaphane (Sulf) for 16h, before cells were lysed and 
probed for expression of heme-oxygenase-1 (HO-1) and actin (n=3). (C-F) AM (C-D) or MDM (E and F) from 
healthy (H) or COPD non-frequent (NF) or frequent (F) exacerbators were pre-treated with vehicle (Sulf -) 
or Sulforaphane (Sulf +) for 16 h, before cells were challenged with non-opsonized (C and E) or opsonized 
(D and F) serotype 14 S. pneumoniae. 4h post-challenge, numbers of intracellular viable bacteria were 
measured, values for 'n=' for H/COPD-NF/COPD-F; (C) 11/19/14, (D) 8/ 10/4, (E) 9/9/5, (F) 8/9/5, 
*=p<0.05, paired t-test. (G and H) AM (G) and MDM (H) from COPD patients or healthy (H) donors were 
pre-treated with sulforaphane before being challenged with non-typeable H. influenzae (NTHi). 4h post 
challenge the numbers of intracellular viable bacteria were measured, values for 'n=' for H/COPD (G)3/4, 
(H) 3/3, *=p<0.05, paired t-test. (I) COPD AM were pre-treated with sulforaphane (+Sulf) before being 
challenged with non-opsonized serotype 14 S. pneumoniae for 4h before extracellular bacteria were killed by 
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the addition of antibiotics. At the designated time post-antibiotics, viable bacteria in duplicate wells were measured
 to, n=3, no significant difference between vehicle and sulf.  
275x385mm (300 x 300 DPI)
Figure 7. The Nrf-2 agonist compound 7 also increases phagocytosis in COPD AM.  
(A and B) COPD monocyte-derived macrophages (MDM) (A), or alveolar macrophages (AM) (B), were pre-
treated with the Nrf-2 agonist Compound 7 for 16h at the designated dose, before cells were lysed and a 
probed for the expression of heme-oxygenase-1 (HO-1), glutamate-cysteine ligase catalytic subunit (GCLC) 
or NADPH:quinone oxidoreductase 1 (NQO1)  by western blot. (C and D) Healthy donor and COPD AM were 
pre-treated with Compound 7 at 5x IC50 (0.065  M), for 16h before being challenged with opsonized (C), 
n=3 healthy, n=5 COPD or non-opsonized (D), n=3 healthy, n=10 COPD, serotype 14 S. pneumoniae for 
4h, after which numbers of intracellular viable bacteria were assessed, **=p<0.01, paired t-test. (E and F) 
Healthy donor and COPD MDM were pre-treated with compound 7 and challenged with opsonized (E), or 
non-opsonized (F), S. pneumoniae as for AM. All n=4, p **=p<0.01, paired t-test.  
173x163mm (300 x 300 DPI) 
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Online Data Supplement 
Opsonic phagocytosis in chronic obstructive pulmonary disease is 
enhanced by Nrf2 agonists.  
Martin A. Bewley, Richard C Budd, Eilise Ryan,  Joby Cole, Paul Collini, Jennifer Marshall, Umme Kolsum, 
Gussie Beech, Richard D. Emes, Irina Tcherniaeva, Guy A. M. Berbers, Sarah R. Walmsley, Gavin 
Donaldson, Jadwiga A. Wedzicha, Iain Kilty, William Rumsey, Yolanda Sanchez, Christopher E. Brightling, 
Louise E. Donnelly, Peter J. Barnes, Dave Singh,  Moira K.B. Whyte and David H. Dockrell, on behalf of 
COPDMAP.
1Supplemental Methods 
Macrophage donors: COPD patients were recruited from the UK Medical Research 
Council (MRC) COPD-MAP consortium, a well-defined clinical cohort of GOLD 
Stage A-D patients (Table E1). Written approved consent was obtained prior to 
inclusion in the study as approved by the National Research Ethics Service 
Committee for Yorkshire and the Humber #11/YH0356 and Greater Manchester 
South # 06/Q1403/156.  Subjects had undergone extensive clinical characterization 
including, visual analogue symptom (VAS) scores for breathlessness, spirometry and 
health status assessment. All patients used in the current study had GOLD stage II or 
III COPD. Controls were healthy ex-smokers (defined as > 6 months smoking 
cessation) without airflow limitation assessed by spirometry and without symptoms of 
COPD by screening questionnaire or on clinical examination. Exacerbation frequency 
was determined by medical history of oral therapy for exacerbation and frequent 
exacerbators were defined as having had ≥ 2 exacerbations in the preceding 12 
months (E1).  Bronchoscopies were performed in the stable state, not during 
exacerbations. Since the yield of samples varied all study participants had an AM 
sample challenged with non-opsonized bacteria but only approximately three-quarters 
had sufficient sample to allow challenge with opsonized bacteria. Similarly, not every 
individual agreed to a blood donation of sufficient yield to allow isolation of 
monocyte-derived macrophages (MDM). Accordingly, approximately three-quarters 
of samples had MDM samples for challenge with non-opsonized bacteria and a 
smaller number enough MDM for challenge with opsonized bacteria. Since the 
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2volume of BAL and the yield of AM varied only approximately half of samples had 
sufficient numbers for further analysis of sulforaphane. 
Assessment scales: Health status and physical activity of the COPD patients was 
evaluated by a number of  validated health-related quality of life (HR-QoL) 
instruments; the St George's Respiratory Questionnaire (SGRQ)(E2), COPD 
Assessment Test (CAT)(E3) and Medical Research Council (MRC) dyspnea scale 
(E4), and with the 6-minute walking distance (6MW) (E5). Scores from these 
evaluations (with the exception of the MRC dyspnea scale) were then plotted against 
that patient’s phagocytosis rates. 
Microbiological assessment: 
Sputum quantitative culture was performed according to standard practice (E6) 
Briefly, the sample was cultured onto suitable agar plates i.e. Columbia blood agar (a 
general growth media), Chocolate agar (for fastidious bacteria), MacConkey agar (for 
Gram-negative bacteria), and COBA agar (Streptococcus selective supplement). The 
plates were incubated for 24h to 48h at 37
°
C and 5% CO2 and identified accordingly
to standard practice using X and V tests (E6). Positive sputum cultures were defined 
as >10
5
 colony forming units.
Broncholalveolar lavage (BAL) was also processed for quantitative polymerase chain 
reaction (qPCR) detection of the common respiratory potentially pathogenic 
microorganisms (PPM) H. influenzae, M. catarrhalis and S. pneumoniae and for 
human rhinovirus (RV) as previously described with a positive result defined as >10
4
copies/ml (E7). Microbiology results were only available for a subset of donors and 
relationships were tested against results for sputum or BAL as illustrated. 
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3Microbiology culture of non-typeable Haemophilus influenzae: 
Non-typable H. influenzae (NCTC 1269) was plated out on chocolate agar overnight 
before cultures were grown to OD 0.6 in brain heart infusion (BHI) (Oxoid) 
supplemented with 20% FCS (Lonza), 20 µg/ml NAD (Sigma) and 10 µg/ml Heme 
(Sigma). 
Analysis of pneumococcal antibodies in bronchoalveolar lavage fluid. 
Pneumococcal serotype-specific IgG antibody concentrations to 13 pneumococcal 
serotypes were measured using a fluorescent bead-based multiplex immunoassay 
(MIA) as described previously by Elberse et al. (E8). In short, BAL samples were 
diluted 1:2 in buffer containing 30 µg/ml cell wall polysaccharide Multi (Statens 
Serum Institute (SSI), Copenhagen, Denmark) and 5% antibody depleted human 
serum. An in-house reference serum calibrated on the international 007 standard 
serum (NIBSC) was diluted twofold in 12 steps and included on each plate together 
with 3 control sera. All capsular polysaccharides were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA) except for polysaccharide 7F and 
19F from SSI, and 6A which was kindly provided by Pfizer Inc. (New York, NY). For 
each sample, median fluorescent intensity was converted to IgG concentration (µg/ml) 
by interpolation from a 5-parameter logistic standard curve. Results were obtained 
using a Bio-plex 200 system with Bio-plex software (version 6.1, Bio-Rad, UK). 
Western blot: Whole cell extracts were isolated using SDS-lysis buffer as described 
before (E9) and equal protein loaded per lane. Proteins were separated by SDS gel 
electrophoresis, blotted onto a PVDF membrane, and blocked for 60 min at room 
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4temperature in PBS containing 0.05% Tween with 5% (v/w) skim milk powder. 
Membranes were incubated overnight at 4°C with antibodies against Exchange 
protein activated by cAMP 1 (EPAC-1) (Rabbit polyclonal, Abcam, 1:2000), RAP-1 
(Rabbit polyclonal, Abcam 1:1000), RAC-1 (Abcam, rabbit polyclonal 1:1000), 
Heme-oxygenase-1 (HO-1) (Santa Cruz, rabbit polyclonal 1:1000), GCLC (Abcam, 
rabbit polyclonal 1:1000),  NQO1 (Abcam, rabbit polyclonal, 1:1000), tubulin 
(Abcam, rabbit monoclonal, 1:1000), or actin (Sigma, rabbit polyclonal, 1:2000). 
Proteins were detected using HRP-conjugated secondary antibodies (1:2000; Dako) 
and ECL (Amersham Pharmacia).  As positive controls for EPAC-1, RAP-1 and 
RAC-1 MDM were treated in hypoxia (1% O2 for 6 h). 
Bacterial binding: Bacterial binding and internalization was assessed by fluorescence 
microscopy (Leica DMRB 1000) (E10). At the designated time after infection cells 
were fixed in 2% paraformaldehyde. Cells were then washed three times in PBS and 
incubated for 15 min with 100 µg of human IgG1 (Sigma), then washed three times in 
PBS and were then incubated with 200 µL PBS containing a 1:20 dilution of serotype 
specific rabbit anti-pneumococcal antibody (Statens Seruminstitut)  for 10 min at 
20°C (E11). Wells were then washed and incubated with 200 µL PBS containing a 
1:20 dilution of fluorescein isothiocyanate (FITC) conjugated goat anti–rabbit IgG Fc 
(Dako) and a 1:20 dilution of goat serum. Cells were then washed and incubated  with 
200 µL PBS containing 0.5 µg/ml 4′6′-diamidino-2-phenylindole (DAPI; Molecular 
Probes). The number of bound (FITC positive, DAPI positive) and internalized 
bacteria (FITC negative, DAPI positive) were counted for at least 200 cells per 
condition (E10). As controls for fluorescence microscopy incubation on ice  for 4 h 
was used as a positive control for adherence, treatment with 100 µg/ml IgG1 (Sigma) 
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was used as a negative control for binding and internalization and treatment of 
bacteria with 20% immune serum as a positive control for internalization. 
 
Cell surface marker expression. For the staining of Fc-gamma receptors, cells were 
blocked with Human TruStain FcX (Biolegend), specially formulated for blocking 
FcR without interfering with antibody-mediated specific staining. Cells were blocked 
for 10 min. at room temperature before being stained with either PE-CD16 (clone 
3G8), Alexa Fluor 488-CD32 (clone FUN-2), PE-CD64 (clone 10.1) or corresponding 
isotype controls (All Biolegend, 5µL/million cells). After staining cells were washed 
in PBS and analyzed by flow cytometry (BD Biosciences FACSCalibur). 
 
Toxicity assays: Nuclear fragmentation and condensation indicative of apoptosis were 
detected at 20 h after compound treatment using 4′6′-diamidino-2-phenylindole 
(DAPI), by reviewers blinded to sample origin. Necrosis was measured by the release 
of lactate dehydrogenase into supernatants using the Cytotox 96 cell viability kit 
(Promega), used according to the manufacturer’s instructions. 
 
Transcriptomic analysis:  Total RNA from alveolar macrophages (AM) of healthy 
volunteers and COPD patients was extracted using TRI reagent (Sigma) and Direct-
Zol
TM
 RNA Miniprep (Zymo research) following the manufacturers protocol. The 
mRNA was then hybridized onto the Affymetrix® HG-U133 plus 2.0 Array 
(Affymetrix Inc, Santa Clara). Raw data was analyzed in R (v 3.3.1) using affyPML 
package to perform background correction using GC Robust Multi-array Average, 
and quantile normalization. Probes whose expression was in the 20
th
 lowest centile 
were removed. Differentially expressed genes were identified using Limma to 
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6calculate Moderated t tests and considered significant if adjusted p value <0.05 
following Benjamini-Hochberg correction. Genes differentially expressed with 
respect to infection were tested for overrepresentation of Gene Ontology (GO) terms 
using a hypergeometric model using GOstats package and figures generated using 
NIPA (available at https://github.com/ADAC-UoN/NIPA) (FDR <0.05) in R. In 
addition network analysis shown in  Figure E6 was generated using BiNGO software 
in Cytoscape. The transcriptomic data is available online in the ArrayExpress 
database at EMBL-EAI .www.ebi.ac.uk/arrayexpress) under accession number E-
MTAB-6491. 
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Figure Legends 
Figure E1. Relationship between bacterial uptake and exacerbation frequency. 
Alveolar macrophages (AM) were collected from patients with COPD and were 
challenged with non-opsonized (NO) or opsonized (O) serotype 14 S. pneumoniae for 
4 h, before extracellular bacteria were killed by the addition of antibiotics. At the 
designated time post-antibiotics, viable bacteria in duplicate wells were measured and 
plotted against exacerbation frequency. ‘n’ values for NO/O by exacerbation 
frequency; 0=20/15, 1=7/4, 2=3/2,3=7/74=3/3,5=2/1. 
Figure E2.  COPD Macrophages show no defect in early-phase bacterial killing. 
(A-D) Alveolar macrophages (AM) (A and B) or monocyte derived macrophages 
(MDM) were collected from patients with COPD (A and C) or healthy donors (B and 
D) and were challenged with non-opsonized or opsonized serotype 14 S. pneumoniae
for 4h, before extracellular bacteria were killed by the addition of antibiotics. At the 
designated time post-antibiotics, viable bacteria in duplicate wells were measured, 
n=3, no significant differences between any groups. 
Figure E3.  COPD alveolar macrophages show defects in uptake of opsonized S. 
pneumoniae. Alveolar macrophages (AM) or monocyte derived macrophages (MDM) 
were collected from patients with COPD or healthy donors and were challenged with 
non-opsonized or opsonized serotype 14 S. pneumoniae for 4h,  before performing 
fluorescence microscopy to determine adherent (green, continuous arrows) and 
internalized bacteria (blue, broken arrows. Representative images are  shown for 
fluorescence microscopy of AM (A)  and MDM (B) with binding shown in the upper 
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row and internalization in the lower row. In these experiments incubation on ice was a 
positive control for binding, IgG1 treatment to block FcγR was a negative control for 
both binding and internalization and treatment with 20% immune serum was a 
positive control for internalization. Pictures are representative of three donors in each 
condition. (C-F) AM (C and E) and MDM (D and F) from healthy and COPD donors 
(non-frequent or frequent exacerbators) were analyzed to record bacterial binding and 
internalization under the same conditions by fluorescence microscopy, n=4. * p<0.05 
by One-way ANOVA. 
 
Figure E4. COPD Macrophages show no defect in Fc-gamma expression or 
expression of EPAC-1 RAP-1 and RAC-1.    
(A-B) Healthy and COPD alveolar macrophages (AM) AM (A) and monocyte derived 
macrophages (MDM) (B) were analyzed for the expression of either CD16, CD32 or 
CD64 by flow cytometry, n=3, no significant differences between healthy or COPD. 
(C-D) Healthy or COPD AM from two individual donors (i and ii) were either mock-
infected (Spn-) or challenged with serotype 14 S. pneumoniae (Spn +). 4h post-
challenge cells were lysed and the expression of EPAC-1, RAP1 and RAC1 assessed 
by western blot. The blot is representative of one of three. (C) Positive controls (+) for 
EPAC-1, RAP-1  and RAC-1 were  hypoxic MDM (as compared to nomoxic MDM (-
)). 
 
Figure E5 Pneumococcal antibodies are detectable in broncholaveolar lavage 
fluid. Bronchoalveolar lavage fluid from 13 healthy and 16 COPD patients was 
analyzed by multiplex immunoassay for presence of pneumococcal antibodies against 
13 S. pneumoniae serotypes. 
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Figure E6. Transcriptional response of AM reveals less differential gene 
expression in COPD in response to infection.  Ontology analysis of Healthy and 
COPD networks following pneumococcal challenge. The overrepresented terms 
(calculated with BiNGO software in Cytoscape, FDR <0.05, Hypergeometric 
clustering) are visualised. The terms for Cellular Response to Stress are highlighted 
by an arrow in each network. 
 
Figure E7. Treatment with Nrf-2 agonists does not induce apoptosis or necrosis. 
COPD alveolar macrophages were pre-treated with sulforaphane (+Sulf) or compound 
7 for 16h. Cells were then assessed for either necrosis (A) or apoptosis (n=3). 
 
Figure E8. Sulforaphane treatment does not modify Fc-gamma expression in 
healthy or COPD macrophages. Healthy or COPD alveolar macrophages (AM)(A) 
or monocyte-derived macrophages (MDM)(B) were pre-treated with sulforaphane 
(+Sulf) for 16h. Cells were then assessed for expression of CD16, CD32 or CD64 by 
flow cytometry, n=3. 
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Table E1: Top differentially regulated gene probes for healthy AM 
Healthy AM MI vs S. pneumoniae 
Affymetrix 
probe ID 
logFC q value Entrez Name Gene name 
206407_s_at 8.271748089 0.00017628 6357 CCL13 C-C motif chemokine ligand 13 
(CCL13) 
205890_s_at 7.470218672 0.000602696 2550 GABBR1 gamma-aminobutyric acid type 
B receptor subunit 1 (GABBR1) 
210873_x_at 7.292943927 0.000639873 200315 APOBEC3A apolipoprotein B mRNA editing 
enzyme catalytic subunit  3A 
(APOBEC3A) 
214022_s_at 7.263546468 0.000978422 8519 IFITM1 interferon induced 
transmembrane protein 1 
(IFITM1) 
202746_at 6.972741506 0.001622634 9452 ITM2A integral membrane protein 
2A( ITM2A) 
203915_at 6.931197241 0.000273857 4283 CXCL9 C-X-C motif chemokine ligand 9 
(CXCL9) 
208450_at 6.685442365 0.000128955 3957 LGALS2 galectin 2(LGALS2) 
209686_at 6.674192457 0.000602696 6285 S100B S100 calcium binding protein B 
(S100B) 
219836_at 6.530204305 0.000676664 79413 ZBED2 zinc finger BED-type containing 
2 (ZBED2) 
204563_at 6.474742419 0.000740994 6402 SELL selectin L (SELL) 
209561_at -5.15603454 0.001764023 7059 THBS3 Thrombospondin 3 (THBS3) 
201131_s_at -5.181392931 0.004915805 999 CDH1 cadherin 1(CDH1) 
214366_s_at -5.330701347 0.029424351 240 ALOX5 arachidonate 5-lipoxygenase 
(ALOX5) 
203716_s_at -5.351919708 0.002898479 1803 DPP4 dipeptidyl peptidase 4(DPP4) 
209728_at -5.641721827 0.000862231 3126 HLA-DRB4 major histocompatibility 
complex, class II, DR beta 4 
(HLA-DRB4) 
211102_s_at -5.745789792 0.035623081 11027 LILRA2 leukocyte immunoglobulin like 
receptor A2 (LILRA2) 
220784_s_at -5.86516063 0.003370561 10911 UTS2 urotensin 2 (UTS2) 
204364_s_at -6.03185733 0.003062235 65055 REEP1 receptor accessory protein 1 
(REEP1) 
219434_at -6.221508302 0.005872442 54210 TREM1 triggering receptor expressed 
on myeloid cells 1 (TREM1) 
217078_s_at -6.546933332 0.037935264 11314 CD300A CD300a molecule (CD300A) 
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Table E2 Top differentially regulated gene probes for COPD AM 
COPD AM MI vs S. pneumoniae 
Affymetrix 
probe ID 
logFC q value Entrez Name Gene name 
204567_s_at 2.014122464 0.048121165 9619 ABCG1 ATP binding cassette subfamily G 
member 1 (ABCG1) 
203315_at 1.979168617 0.031927439 8440 NCK2 NCK adaptor protein 2(NCK2) 
219497_s_at 1.853658768 0.029753664 53335 BCL11A B-cell CLL/lymphoma 
11A(BCL11A) 
205687_at 1.817410224 0.01483341 56061 UBFD1 ubiquitin family domain 
containing 1(UBFD1) 
201848_s_at 1.816156867 0.036585488 664 BNIP3 BCL2 interacting protein 3(BNIP3) 
204972_at 1.811343652 0.043243889 4939 OAS2 2'-5'-oligoadenylate synthetase 
2(OAS2) 
211113_s_at 1.807154615 0.031256828 9619 ABCG1 ATP Binding Cassette Subfamily G 
Member 1 (ABCG1) 
205552_s_at 1.610119973 0.018262832 4938 OAS1 2'-5'-oligoadenylate synthetase 
1(OAS1) 
215037_s_at 1.592545166 0.033041465 598 BCL2L1 BCL2 like 1(BCL2L1) 
202869_at 1.532562476 0.016248444 4938 OAS1 2'-5'-oligoadenylate synthetase 
1(OAS1) 
201791_s_at -1.854527497 0.034527556 1717 DHCR7 7-dehydrocholesterol 
reductase(DHCR7) 
204790_at -1.864061665 0.01483341 4092 SMAD7 SMAD family member 7(SMAD7) 
205403_at -2.034174738 0.031927439 7850 IL1R2 interleukin 1 receptor type 
2(IL1R2) 
212282_at -2.035476503 0.044318817 27346 TMEM97 transmembrane protein 
97(TMEM97) 
202539_s_at -2.181882025 0.036240919 3156 HMGCR 3-hydroxy-3-methylglutaryl-CoA 
reductase(HMGCR) 
209218_at -2.256973195 0.041926617 6713 SQLE squalene epoxidase(SQLE) 
212560_at -2.257718048 0.038373402 6653 SORL1 sortilin related receptor 1(SORL1) 
213577_at -2.432492887 0.026458227 6713 SQLE squalene epoxidase(SQLE) 
210004_at -2.510144406 0.015716731 4973 OLR1 oxidized low density lipoprotein 
receptor 1(OLR1) 
207826_s_at -3.593137708 0.006341014 3399 ID3 inhibitor of DNA binding 3, HLH 
protein(ID3) 
Page 50 of 88
 12
Table E3 Differentially regulated gene probes belonging to GO term Cellular 
Response to Stress 
 
Healthy 
Affy probe ID logFC q value Name Gene name 
209686_at 6.6742 0.0006 S100B S100 calcium binding protein B 
(S100B) 
226315_at 1.3878 0.0007 ZNF830 zinc finger protein 830 (ZNF830) 
207785_s_at 1.2269 0.0007 RBPJ recombination signal binding protein 
for immunoglobulin kappa J region 
(RBPJ) 
205904_at -1.9848 0.0008 MICA MHC class I polypeptide-related 
sequence A (MICA) 
205967_at 3.6889 0.0008 HIST1H4C histone cluster 1 H4 family member c 
(HIST1H4C) 
204224_s_at 5.3079 0.0008 GCH1 GTP cyclohydrolase 1 (GCH1) 
200878_at -1.6743 0.0009 EPAS1 endothelial PAS domain protein 1 
(EPAS1) 
238831_at -2.4749 0.0010 TMEM33 transmembrane protein 33 
(TMEM33) 
217550_at -2.8103 0.0010 ATF6 activating transcription factor 6 
(ATF6) 
204279_at 4.1151 0.0010 PSMB9 proteasome subunit beta 9(PSMB9) 
218041_x_at -1.8503 0.0011 SLC38A2 solute carrier family 38 member 2 
(SLC38A2) 
204466_s_at -5.0755 0.0011 SNCA synuclein alpha (SNCA) 
202503_s_at 5.5584 0.0011 PCLAF PCNA clamp associated factor 
(PCLAF) 
227228_s_at 4.2187 0.0012 CCDC88C coiled-coil domain containing 88C 
(CCDC88C) 
203611_at 1.5877 0.0013 TERF2 telomeric repeat binding factor 2 
(TERF2) 
209959_at 6.1518 0.0014 NR4A3 nuclear receptor subfamily 4 group A 
member 3 (NR4A3) 
206488_s_at -2.1956 0.0014 CD36 CD36 molecule (CD36) 
208808_s_at 3.9025 0.0014 HMGB2 high mobility group box 2 (HMGB2) 
221700_s_at 1.3430 0.0015 UBA52 ubiquitin A-52 residue ribosomal 
protein fusion product 1 (UBA52) 
224833_at 4.4827 0.0015 ETS1 ETS proto-oncogene 1, transcription 
factor (ETS1) 
220924_s_at -1.9034 0.0015 SLC38A2 solute carrier family 38 member 2 
(SLC38A2) 
209555_s_at -2.4553 0.0015 CD36 CD36 molecule(CD36) 
1558549_s_at -4.5040 0.0015 VNN1 vanin 1 (VNN1) 
226248_s_at 4.0831 0.0015 KIAA1324 KIAA1324 (KIAA1324) 
200016_x_at 1.1062 0.0015 HNRNPA1 heterogeneous nuclear 
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ribonucleoprotein A1 (HNRNPA1) 
228999_at 2.8726 0.0015 CHD2 chromodomain helicase DNA binding 
protein 2 (CHD2) 
225655_at 3.9528 0.0015 UHRF1 ubiquitin like with PHD and ring 
finger domains 1 (UHRF1) 
201762_s_at 1.8409 0.0015 PSME2 proteasome activator subunit 2 
(PSME2) 
213356_x_at 1.1694 0.0015 HNRNPA1 heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) 
202644_s_at 2.7125 0.0015 TNFAIP3 TNF alpha induced protein 3 
(TNFAIP3) 
224847_at 1.6661 0.0015 CDK6 cyclin dependent kinase 6 (CDK6) 
234000_s_at -2.0247 0.0015 HACD3 3-hydroxyacyl-CoA dehydratase 3 
(HACD3) 
209304_x_at 1.6855 0.0016 GADD45B growth arrest and DNA damage 
inducible beta (GADD45B) 
200814_at 2.1663 0.0016 PSME1 proteasome activator subunit 1 
(PSME1) 
203510_at -4.5338 0.0016 MET MET proto-oncogene, receptor 
tyrosine kinase (MET) 
238653_at 1.3389 0.0016 LRIG2 leucine rich repeats and 
immunoglobulin like domains 2 
(LRIG2) 
220384_at 3.4506 0.0016 NME8 NME/NM23 family member 8(NME8) 
212634_at -1.3049 0.0016 UFL1 UFM1 specific ligase 1 (UFL1) 
205197_s_at -4.3706 0.0016 ATP7A ATPase copper transporting alpha 
(ATP7A) 
236341_at 5.7210 0.0016 CTLA4 cytotoxic T-lymphocyte associated 
protein 4 (CTLA4) 
203553_s_at -1.5803 0.0017 MAP4K5 mitogen-activated protein kinase 
kinase kinase kinase 5 (MAP4K5) 
220949_s_at 2.1958 0.0017 C7orf49 chromosome 7 open reading frame 
49 (C7orf49) 
203445_s_at 1.3278 0.0017 CTDSP2 CTD small phosphatase 2 (CTDSP2) 
207113_s_at 3.9122 0.0017 TNF tumor necrosis factor (TNF) 
202153_s_at 1.2330 0.0017 NUP62 nucleoporin 62 (NUP62) 
37145_at 5.7873 0.0017 GNLY Granulysin (GNLY) 
210426_x_at 2.9696 0.0018 RORA RAR related orphan receptor A 
(RORA) 
217373_x_at -1.5002 0.0018 MDM2 MDM2 proto-oncogene (MDM2) 
217807_s_at 2.6021 0.0018 NOP53 NPR2-like, GATOR1 complex subunit 
(NPRL2) 
218197_s_at -1.8142 0.0018 OXR1 oxidation resistance 1 (OXR1) 
202181_at 1.0875 0.0019 SUSD6 sushi domain containing 6 (SUSD6) 
226991_at 4.1911 0.0019 NFATC2 nuclear factor of activated T-cells 2 
(NFATC2) 
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200944_s_at 1.6260 0.0019 HMGN1 high mobility group nucleosome 
binding domain 1 (HMGN1) 
205965_at 1.2119 0.0019 BATF basic leucine zipper ATF-like 
transcription factor (BATF) 
215223_s_at 2.2428 0.0019 SOD2 superoxide dismutase 2, 
mitochondrial (SOD2) 
226032_at 1.2471 0.0019 CASP2 caspase 2 (CASP2) 
39248_at 3.9050 0.0019 AQP3 aquaporin 3 (Gill blood group) 
(AQP3) 
209033_s_at 1.1523 0.0020 DYRK1A dual specificity tyrosine 
phosphorylation regulated kinase 1A 
(DYRK1A) 
207819_s_at -3.4365 0.0020 ABCB4 ATP binding cassette subfamily B 
member 4 (ABCB4) 
207072_at 3.6333 0.0020 IL18RAP interleukin 18 receptor accessory 
protein (IL18RAP) 
225053_at 1.2457 0.0021 CNOT7 CCR4-NOT transcription complex 
subunit 7 (CNOT7) 
205905_s_at -2.3166 0.0022 MICA MHC class I polypeptide-related 
sequence A (MICA) 
200019_s_at 1.9603 0.0022 SYVN1 synoviolin 1(SYVN1) 
210479_s_at 3.2586 0.0022 RORA RAR related orphan receptor A 
(RORA) 
226682_at 3.2016 0.0022 RORA RAR related orphan receptor A 
(RORA) 
200896_x_at 1.4362 0.0022 HDGF hepatoma-derived growth factor 
(HDGF) 
205495_s_at 5.6931 0.0023 GNLY Granulysin (GNLY) 
203984_s_at 1.4089 0.0024 CASP9 caspase 9 (CASP9) 
48531_at 1.7755 0.0024 TNIP2 TNFAIP3 interacting protein 2 
(TNIP2) 
224162_s_at 2.5697 0.0024 FBXO31 F-box protein 31 (FBXO31) 
206235_at -2.0013 0.0024 LIG4 DNA ligase 4 (LIG4) 
1552703_s_at 2.1788 0.0025 CARD16 caspase recruitment domain family 
member 16 (CARD16) 
200879_s_at -3.4515 0.0025 EPAS1 endothelial PAS domain protein 1 
(EPAS1) 
204908_s_at 3.1879 0.0025 BCL3 B-cell CLL/lymphoma 3 (BCL3) 
212345_s_at -1.1560 0.0026 CREB3L2 cAMP responsive element binding 
protein 3 like 2 (CREB3L2) 
231927_at -1.1676 0.0026 ATF6 activating transcription factor 6 
(ATF6) 
225606_at 3.8722 0.0027 BCL2L11 BCL2 like 11 (BCL2L11) 
202061_s_at -1.5678 0.0027 SEL1L SEL1L ERAD E3 ligase adaptor subunit 
(SEL1L) 
221473_x_at -1.3400 0.0028 SERINC3 serine incorporator 3 (SERINC3) 
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227931_at -1.6590 0.0028 INO80D INO80 complex subunit D (INO80D) 
209294_x_at -1.2891 0.0028 TNFRSF10
B 
TNF receptor superfamily member 
10b (TNFRSF10B) 
222982_x_at -1.4575 0.0028 SLC38A2 solute carrier family 38 member 2 
(SLC38A2) 
216264_s_at -2.9882 0.0028 LAMB2 laminin subunit beta 2 (LAMB2) 
209239_at 2.4615 0.0028 NFKB1 nuclear factor kappa B subunit 1 
(NFKB1) 
203418_at 3.2141 0.0029 CCNA2 cyclin A2 (CCNA2) 
203628_at -2.2550 0.0029 IGF1R insulin like growth factor 1 receptor 
(IGF1R) 
224731_at 1.3281 0.0029 HMGB1 high mobility group box 1 (HMGB1) 
201830_s_at 3.1156 0.0029 NET1 neuroepithelial cell transforming 1 
(NET1) 
200797_s_at 1.4190 0.0029 MCL1 BCL2 family apoptosis regulator 
(MCL1) 
202243_s_at 1.3195 0.0030 PSMB4 proteasome subunit beta 4 (PSMB4) 
205180_s_at -1.4435 0.0030 ADAM8 ADAM metallopeptidase domain 8 
(ADAM8) 
223278_at 3.0753 0.0030 GJB2 gap junction protein beta 2 (GJB2) 
205179_s_at -2.3409 0.0030 ADAM8 ADAM metallopeptidase domain 8 
(ADAM8) 
207827_x_at -4.1027 0.0030 SNCA synuclein alpha (SNCA) 
204318_s_at 1.8301 0.0030 GTSE1 G2 and S-phase expressed 1 (GTSE1) 
203460_s_at -1.0503 0.0031 PSEN1 presenilin 1 (PSEN1) 
222404_x_at -1.9551 0.0031 HACD3 3-hydroxyacyl-CoA dehydratase 3 
(HACD3) 
218172_s_at -1.2967 0.0031 DERL1 derlin 1 (DERL1) 
203214_x_at 3.8980 0.0032 CDK1 cyclin dependent kinase 1 (CDK1) 
225924_at -2.2151 0.0032 FNIP2 folliculin interacting protein 2 
(FNIP2) 
207574_s_at 2.0552 0.0033 GADD45B growth arrest and DNA damage 
inducible beta (GADD45B) 
200642_at 1.1138 0.0033 SOD1 superoxide dismutase 1, soluble 
(SOD1) 
231736_x_at -1.0800 0.0033 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
211327_x_at -1.4604 0.0034 HFE Hemochromatosis (HFE) 
211769_x_at -1.4732 0.0034 SERINC3 serine incorporator 3 (SERINC3) 
214280_x_at 1.5241 0.0034 HNRNPA1 heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1) 
207347_at 2.6408 0.0035 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
218738_s_at 1.6571 0.0036 RNF138 ring finger protein 138 (RNF138) 
205550_s_at -1.2715 0.0036 BABAM2 BRISC and BRCA1 A complex member 
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2 (BABAM2) 
201531_at 1.7311 0.0036 ZFP36 ZFP36 ring finger protein (ZFP36) 
228766_at -2.2228 0.0036 CD36 CD36 molecule (CD36) 
1553402_a_at -2.7985 0.0036 HFE hemochromatosis(HFE) 
226460_at -2.5348 0.0037 FNIP2 folliculin interacting protein 2 
(FNIP2) 
208760_at 2.7396 0.0037 UBE2I ubiquitin conjugating enzyme E2 I 
(UBE2I) 
219625_s_at -2.1514 0.0038 COL4A3BP collagen type IV alpha 3 binding 
protein (COL4A3BP) 
236266_at 1.6067 0.0038 RORA RAR related orphan receptor A 
(RORA) 
210793_s_at 2.7189 0.0038 NUP98 nucleoporin 98 (NUP98) 
209503_s_at 1.3352 0.0038 PSMC5 proteasome 26S subunit, ATPase 5  
(PSMC5) 
205590_at 2.6805 0.0039 RASGRP1 RAS guanyl releasing protein 1 
(RASGRP1) 
201272_at -1.4230 0.0039 AKR1B1 aldo-keto reductase family 1 
member B (AKR1B1) 
204533_at 4.9554 0.0039 CXCL10 C-X-C motif chemokine ligand 10 
(CXCL10) 
218069_at 1.3613 0.0040 DCTPP1 dCTP pyrophosphatase 1 (DCTPP1) 
218403_at 1.1052 0.0041 TRIAP1 TP53 regulated inhibitor of apoptosis 
1 (TRIAP1) 
201812_s_at 1.6611 0.0041 TOMM7 translocase of outer mitochondrial 
membrane 7 (TOMM7) 
204467_s_at -2.2398 0.0041 SNCA synuclein alpha (SNCA) 
225160_x_at -3.3167 0.0041 MDM2 MDM2 proto-oncogene (MDM2) 
222432_s_at -1.6379 0.0041 CCDC47 coiled-coil domain containing 47 
(CCDC47) 
211332_x_at -1.4186 0.0041 HFE Hemochromatosis (HFE) 
211546_x_at -3.0292 0.0041 SNCA synuclein alpha (SNCA) 
215997_s_at -1.1916 0.0041 CUL4B cullin 4B (CUL4B) 
1554462_a_at -1.8792 0.0041 DNAJB9 DnaJ heat shock protein family 
(Hsp40) member B9 (DNAJB9) 
201737_s_at -2.9591 0.0042 MARCH6 membrane associated ring-CH-
type finger 6 (MARCH6) 
209112_at 2.9984 0.0042 CDKN1B cyclin dependent kinase inhibitor 1B 
(CDKN1B) 
222763_s_at 1.7050 0.0042 WDR33 WD repeat domain 33 (WDR33) 
224918_x_at -1.0379 0.0042 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
201649_at 2.3181 0.0043 UBE2L6 ubiquitin conjugating enzyme E2 L6 
(UBE2L6) 
201345_s_at 1.1380 0.0044 UBE2D2 ubiquitin conjugating enzyme E2 D2 
(UBE2D2) 
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200943_at 1.5113 0.0045 HMGN1 high mobility group nucleosome 
binding domain 1 (HMGN1) 
204009_s_at 1.2088 0.0045 KRAS KRAS proto-oncogene, GTPase(KRAS) 
229290_at -3.4747 0.0045 DAPL1 death associated protein like 1 
(DAPL1) 
213226_at 2.8150 0.0045 CCNA2 cyclin A2(CCNA2) 
225135_at 2.7524 0.0046 SIN3A SIN3 transcription regulator family 
member A (SIN3A) 
213095_x_at 2.0801 0.0046 AIF1 allograft inflammatory factor 1 (AIF1) 
226507_at 1.0012 0.0046 PAK1 p21 (RAC1) activated kinase 1 (PAK1) 
225763_at 3.3710 0.0047 RCSD1 RCSD domain containing 1 (RCSD1) 
206087_x_at -1.5647 0.0047 HFE Hemochromatosis (HFE) 
238005_s_at 1.9612 0.0047 SIN3A SIN3 transcription regulator family 
member A (SIN3A) 
212240_s_at 1.6710 0.0048 PIK3R1 phosphoinositide-3-kinase regulatory 
subunit 1 (PIK3R1) 
218609_s_at 1.9037 0.0048 NUDT2 nudix hydrolase 2 (NUDT2) 
228442_at 3.9652 0.0048 NFATC2 nuclear factor of activated T-cells 2 
(NFATC2) 
204959_at 2.5601 0.0048 MNDA myeloid cell nuclear differentiation 
antigen (MNDA) 
202063_s_at -2.2928 0.0049 SEL1L SEL1L ERAD E3 ligase adaptor subunit 
(SEL1L) 
220987_s_at 2.5271 0.0049 NUAK2 NUAK family kinase 2 (NUAK2) 
203379_at 1.1304 0.0049 RPS6KA1 ribosomal protein S6 kinase A1 
(RPS6KA1) 
232064_at -1.1974 0.0050 FER FER tyrosine kinase (FER) 
208827_at 1.2966 0.0050 PSMB6 proteasome subunit beta 6 (PSMB6) 
202164_s_at 1.0752 0.0051 CNOT8 CCR4-NOT transcription complex 
subunit 8 (CNOT8) 
204798_at 4.2929 0.0052 MYB MYB proto-oncogene, transcription 
factor (MYB) 
209619_at 2.5167 0.0052 CD74 CD74 molecule (CD74) 
225838_at 1.2063 0.0053 EPC2 enhancer of polycomb homolog 2 
(EPC2) 
201829_at 2.3673 0.0053 NET1 neuroepithelial cell transforming 1 
(NET1) 
226295_at 1.5538 0.0053 ITFG2 integrin alpha FG-GAP repeat 
containing 2 (ITFG2) 
203525_s_at -1.5824 0.0053 APC APC, WNT signaling pathway 
regulator (APC) 
201202_at 2.0012 0.0054 PCNA proliferating cell nuclear antigen 
(PCNA) 
230425_at -1.4333 0.0054 EPHB1 EPH receptor B1 (EPHB1) 
214084_x_at 2.9014 0.0054 NCF1 neutrophil cytosolic factor 1 (NCF1) 
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200798_x_at 1.4244 0.0055 MCL1 BCL2 family apoptosis regulator 
(MCL1) 
202724_s_at 1.5573 0.0055 FOXO1 forkhead box O1 (FOXO1) 
209901_x_at 2.1444 0.0055 AIF1 allograft inflammatory factor 1 (AIF1) 
212676_at -1.7643 0.0056 NF1 neurofibromin 1 (NF1) 
225252_at 1.0819 0.0056 SRXN1 sulfiredoxin 1 (SRXN1) 
202306_at 1.6480 0.0056 POLR2G RNA polymerase II subunit G 
(POLR2G) 
218465_at -1.3747 0.0057 TMEM33 transmembrane protein 33 
(TMEM33) 
1552263_at 2.1817 0.0057 MAPK1 mitogen-activated protein kinase 1 
(MAPK1) 
201250_s_at -1.3782 0.0057 SLC2A1 solute carrier family 2 member 1 
(SLC2A1) 
225364_at 1.1928 0.0057 STK4 serine/threonine kinase 4 (STK4) 
205733_at 3.3307 0.0057 BLM Bloom syndrome RecQ like helicase 
(BLM) 
1552701_a_at 2.8111 0.0058 CARD16 caspase recruitment domain family 
member 16 (CARD16) 
206271_at 1.9634 0.0058 TLR3 toll like receptor 3(TLR3) 
218250_s_at 1.3350 0.0058 CNOT7 CCR4-NOT transcription complex 
subunit 7 (CNOT7) 
215051_x_at 1.8362 0.0058 AIF1 allograft inflammatory factor 1 (AIF1) 
203213_at 4.7116 0.0059 CDK1 cyclin dependent kinase 1 (CDK1) 
228528_at 1.4066 0.0059 MIR29B2 microRNA 29b-2 (MIR29B2) 
201292_at 4.6705 0.0059 TOP2A topoisomerase (DNA) II alpha 
(TOP2A) 
221666_s_at 2.1472 0.0060 PYCARD PYD and CARD domain containing 
(PYCARD) 
202659_at 2.7855 0.0060 PSMB10 proteasome subunit beta 10 
(PSMB10) 
229119_s_at 1.7095 0.0061 ZSWIM7 zinc finger SWIM-type containing 7 
(ZSWIM7) 
202786_at 3.3043 0.0062 STK39 serine/threonine kinase 39 (STK39) 
225196_s_at 1.8963 0.0062 MRPS26 mitochondrial ribosomal protein S26 
(MRPS26) 
205844_at -3.9550 0.0063 VNN1 vanin 1 (VNN1) 
230285_at 2.8850 0.0063 SVIP small VCP interacting protein (SVIP) 
205960_at -2.4753 0.0064 PDK4 pyruvate dehydrogenase kinase 4 
(PDK4) 
222903_s_at -1.1056 0.0064 CPEB1 cytoplasmic polyadenylation element 
binding protein 1 (CPEB1) 
225837_at 3.3714 0.0064 RHNO1 RAD9-HUS1-RAD1 interacting nuclear 
orphan 1 (RHNO1) 
224734_at 1.6224 0.0064 HMGB1 high mobility group box 1 (HMGB1) 
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1552798_a_at -1.8891 0.0065 TLR4 toll like receptor 4 (TLR4) 
1565162_s_at -1.5077 0.0065 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
224700_at -1.1908 0.0067 STT3B STT3B, catalytic subunit of the 
oligosaccharyltransferase complex 
(STT3B) 
212955_s_at 1.1254 0.0067 POLR2I RNA polymerase II subunit I (POLR2I) 
238311_at -2.1781 0.0068 UFL1 UFM1 specific ligase 1 (UFL1) 
225344_at 1.3596 0.0068 NCOA7 nuclear receptor coactivator 7 
(NCOA7) 
230127_at -3.0843 0.0068 MIR222 microRNA 222 (MIR222) 
230127_at -3.0843 0.0068 MIR221 microRNA 221 (MIR221) 
222642_s_at -2.1825 0.0069 TMEM33 transmembrane protein 33 
(TMEM33) 
208878_s_at 1.3135 0.0069 PAK2 p21 (RAC1) activated kinase 2 (PAK2) 
226547_at 1.5238 0.0070 KAT6A lysine acetyltransferase 6A (KAT6A) 
222569_at -1.4495 0.0070 UGGT1 UDP-glucose glycoprotein 
glucosyltransferase 1 (UGGT1) 
225099_at 1.2510 0.0070 FBXO45 F-box protein 45 (FBXO45) 
243869_at 1.0727 0.0070 CCDC88C coiled-coil domain containing 88C 
(CCDC88C) 
201589_at 1.4712 0.0071 SMC1A structural maintenance of 
chromosomes 1A (SMC1A) 
1559946_s_at 1.5700 0.0071 RUVBL2 RuvB like AAA ATPase 2 (RUVBL2) 
239328_at 2.0917 0.0071 RCSD1 RCSD domain containing 1 (RCSD1) 
1555808_a_at -3.1544 0.0071 EXD2 exonuclease 3'-5' domain containing 
2 (EXD2) 
221521_s_at 3.2555 0.0073 GINS2 GINS complex subunit 2 (GINS2) 
201236_s_at 2.2976 0.0074 BTG2 BTG anti-proliferation factor 2 
(BTG2) 
204751_x_at -1.9213 0.0076 DSC2 desmocollin 2 (DSC2) 
212022_s_at 2.7573 0.0076 MKI67 marker of proliferation Ki-67 (MKI67) 
227545_at 1.6685 0.0077 BARD1 BRCA1 associated RING domain 1 
(BARD1) 
225492_at -1.3006 0.0078 TMEM33 transmembrane protein 33 
(TMEM33) 
224778_s_at -1.7326 0.0078 TAOK1 TAO kinase 1 (TAOK1) 
225207_at -3.1276 0.0079 PDK4 pyruvate dehydrogenase kinase 4 
(PDK4) 
201489_at 1.2158 0.0081 PPIF peptidylprolyl isomerase F (PPIF) 
201174_s_at 1.3594 0.0081 TERF2IP TERF2 interacting protein (TERF2IP) 
228650_at 1.5387 0.0081 POLR2D RNA polymerase II subunit D 
(POLR2D) 
226170_at 1.1691 0.0082 EYA3 EYA transcriptional coactivator and 
phosphatase 3 (EYA3) 
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201400_at 1.3774 0.0082 PSMB3 proteasome subunit beta 3 (PSMB3) 
200651_at 1.3886 0.0082 RACK1 receptor for activated C kinase 1 
(RACK1) 
203415_at 1.2492 0.0083 PDCD6 programmed cell death 6 (PDCD6) 
211330_s_at -2.8336 0.0083 HFE Hemochromatosis (HFE) 
224666_at 1.8143 0.0084 NSMCE1 NSE1 homolog, SMC5-SMC6 complex 
component (NSMCE1) 
223243_s_at -1.9093 0.0084 EDEM3 ER degradation enhancing alpha-
mannosidase like protein 3 (EDEM3) 
223229_at 2.5335 0.0085 UBE2T ubiquitin conjugating enzyme E2 T 
(UBE2T) 
223466_x_at -1.9873 0.0085 COL4A3BP collagen type IV alpha 3 binding 
protein (COL4A3BP) 
212685_s_at -1.1941 0.0085 TBL2 transducin beta like 2 (TBL2) 
206686_at -1.6488 0.0086 PDK1 pyruvate dehydrogenase kinase 1 
(PDK1) 
212099_at 2.9696 0.0087 RHOB ras homolog family member B 
(RHOB) 
210218_s_at 1.7682 0.0087 SP100 SP100 nuclear antigen (SP100) 
204286_s_at 2.7352 0.0087 PMAIP1 phorbol-12-myristate-13-acetate-
induced protein 1 (PMAIP1) 
1558143_a_at 2.4384 0.0088 BCL2L11 BCL2 like 11 (BCL2L11) 
202213_s_at -1.4501 0.0089 CUL4B cullin 4B (CUL4B) 
225922_at -1.5750 0.0090 FNIP2 folliculin interacting protein 2 
(FNIP2) 
203185_at 1.0784 0.0091 RASSF2 Ras association domain family 
member 2 (RASSF2) 
208510_s_at -1.2364 0.0091 PPARG peroxisome proliferator activated 
receptor gamma (PPARG) 
209230_s_at -2.0579 0.0092 NUPR1 nuclear protein 1, transcriptional 
regulator (NUPR1) 
225123_at 2.7206 0.0093 SESN3 sestrin 3 (SESN3) 
203241_at 1.2243 0.0094 UVRAG UV radiation resistance associated 
(UVRAG) 
203719_at 1.3789 0.0094 ERCC1 ERCC excision repair 1, endonuclease 
non-catalytic subunit (ERCC1) 
200039_s_at 1.1403 0.0095 PSMB2 proteasome subunit beta 2 (PSMB2) 
203322_at 1.4707 0.0095 ADNP2 ADNP homeobox 2 (ADNP2) 
242352_at 1.7493 0.0096 NIPBL NIPBL, cohesin loading factor (NIPBL) 
216944_s_at -1.3244 0.0097 ITPR1 inositol 1,4,5-trisphosphate receptor 
type 1 (ITPR1) 
214647_s_at -3.1687 0.0097 HFE Hemochromatosis (HFE) 
200017_at 1.2467 0.0099 RPS27A ribosomal protein S27a (RPS27A) 
218505_at 1.2044 0.0099 WDR59 WD repeat domain 59 (WDR59) 
206554_x_at 2.0061 0.0100 SETMAR SET domain and mariner transposase 
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fusion gene (SETMAR) 
212678_at -1.6486 0.0100 NF1 neurofibromin 1 (NF1) 
214352_s_at 1.1980 0.0100 KRAS KRAS proto-oncogene, GTPase 
(KRAS) 
213682_at 1.6406 0.0101 NUP50 nucleoporin 50 (NUP50) 
209139_s_at 1.3821 0.0102 PRKRA protein activator of interferon 
induced protein kinase EIF2AK2 
(PRKRA) 
202516_s_at -1.4618 0.0102 DLG1 discs large MAGUK scaffold protein 1 
(DLG1) 
208988_at 1.4209 0.0103 KDM2A lysine demethylase 2A (KDM2A) 
242751_at -1.6397 0.0103 PRDX6 peroxiredoxin 6 (PRDX6) 
242197_x_at -1.6963 0.0104 CD36 CD36 molecule (CD36) 
218979_at 1.3828 0.0104 RMI1 RecQ mediated genome instability 1 
(RMI1) 
228281_at 3.1577 0.0104 DDIAS DNA damage induced apoptosis 
suppressor (DDIAS) 
209539_at 1.1853 0.0105 ARHGEF6 Rac/Cdc42 guanine nucleotide 
exchange factor 6 (ARHGEF6) 
209111_at 1.9760 0.0106 RNF5 ring finger protein 5 (RNF5) 
201459_at 1.2695 0.0107 RUVBL2 RuvB like AAA ATPase 2 (RUVBL2) 
225227_at 1.6918 0.0107 SKIL SKI like proto-oncogene (SKIL) 
204566_at 1.1329 0.0107 PPM1D protein phosphatase, Mg2+/Mn2+ 
dependent 1D (PPM1D) 
212594_at 1.5576 0.0107 PDCD4 programmed cell death 4 (neoplastic 
transformation inhibitor) (PDCD4) 
202539_s_at -1.3987 0.0107 HMGCR 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) 
211566_x_at -1.0153 0.0108 BABAM2 BRISC and BRCA1 A complex member 
2 (BABAM2) 
232160_s_at 2.1464 0.0109 TNIP2 TNFAIP3 interacting protein 2 
(TNIP2) 
203246_s_at 1.2654 0.0110 NPRL2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
209507_at 2.0217 0.0113 RPA3 replication protein A3 (RPA3) 
212106_at -1.4907 0.0113 FAF2 Fas associated factor family member 
2 (FAF2) 
202413_s_at 1.4013 0.0113 USP1 ubiquitin specific peptidase 1 (USP1) 
211329_x_at -1.4858 0.0113 HFE Hemochromatosis (HFE) 
204780_s_at 1.2127 0.0114 FAS Fas cell surface death receptor (FAS) 
204127_at 1.9537 0.0115 RFC3 replication factor C subunit 3 (RFC3) 
226760_at -1.1058 0.0116 MBTPS2 membrane bound transcription 
factor peptidase, site 2 (MBTPS2) 
202721_s_at -1.2262 0.0117 GFPT1 glutamine--fructose-6-phosphate 
transaminase 1 (GFPT1) 
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223465_at -1.4203 0.0117 COL4A3BP collagen type IV alpha 3 binding 
protein (COL4A3BP) 
222476_at 1.4670 0.0120 CNOT6 CCR4-NOT transcription complex 
subunit 6 (CNOT6) 
200803_s_at -1.1438 0.0121 TMBIM6 transmembrane BAX inhibitor motif 
containing 6 (TMBIM6) 
210148_at -2.2230 0.0121 HIPK3 homeodomain interacting protein 
kinase 3 (HIPK3) 
201241_at -1.0058 0.0122 DDX1 DEAD-box helicase 1 (DDX1) 
238420_at -1.8221 0.0123 TAOK1 TAO kinase 1 (TAOK1) 
233421_s_at -1.0662 0.0124 NUP133 nucleoporin 133 (NUP133) 
203554_x_at 2.4385 0.0125 PTTG1 pituitary tumor-transforming 
1(PTTG1) 
222600_s_at -2.0859 0.0125 UBA6 ubiquitin like modifier activating 
enzyme 6 (UBA6) 
201161_s_at 1.1163 0.0126 YBX3 Y-box binding protein 3 (YBX3) 
202064_s_at -2.0579 0.0126 SEL1L SEL1L ERAD E3 ligase adaptor subuni 
t(SEL1L) 
224780_at 1.4898 0.0127 RBM17 RNA binding motif protein 17 
(RBM17) 
204484_at 1.1172 0.0128 PIK3C2B phosphatidylinositol-4-phosphate 3-
kinase catalytic subunit type 2 beta 
(PIK3C2B) 
205386_s_at -1.6688 0.0128 MDM2 MDM2 proto-oncogene (MDM2) 
219035_s_at 1.7347 0.0129 RNF34 ring finger protein 34 (RNF34) 
218117_at 1.1157 0.0130 RBX1 ring-box 1 (RBX1) 
222494_at 1.3845 0.0130 FOXN3 forkhead box N3 (FOXN3) 
213137_s_at 2.5706 0.0131 PTPN2 protein tyrosine phosphatase, non-
receptor type 2 (PTPN2) 
219007_at 1.4048 0.0131 NUP43 nucleoporin 43 (NUP43) 
231769_at 1.7185 0.0131 FBXO6 F-box protein 6 (FBXO6) 
209341_s_at 1.1861 0.0132 IKBKB inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase beta 
(IKBKB) 
218845_at 1.2237 0.0132 DUSP22 dual specificity phosphatase 22 
(DUSP22) 
208744_x_at -1.5729 0.0134 HSPH1 heat shock protein family H (Hsp110) 
member 1 (HSPH1) 
226157_at 1.0799 0.0135 TFDP2 transcription factor Dp-2 (TFDP2) 
204285_s_at 2.2882 0.0136 PMAIP1 phorbol-12-myristate-13-acetate-
induced protein 1 (PMAIP1) 
204781_s_at 1.4655 0.0136 FAS Fas cell surface death receptor (FAS) 
224972_at 1.3415 0.0137 ROMO1 reactive oxygen species modulator 1 
(ROMO1) 
208875_s_at 2.3841 0.0140 PAK2 p21 (RAC1) activated kinase 2 (PAK2) 
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1294_at 2.3040 0.0141 UBA7 ubiquitin like modifier activating 
enzyme 7 (UBA7) 
206181_at 3.7115 0.0142 SLAMF1 signaling lymphocytic activation 
molecule family member 1 (SLAMF1) 
218498_s_at -1.4255 0.0142 ERO1A endoplasmic reticulum 
oxidoreductase 1 alpha (ERO1A) 
216248_s_at 3.3321 0.0142 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
203062_s_at 1.8885 0.0142 MDC1 mediator of DNA damage checkpoint 
1 (MDC1) 
204767_s_at 1.9439 0.0143 FEN1 flap structure-specific endonuclease 
1 (FEN1) 
201370_s_at 2.1983 0.0144 CUL3 cullin 3 (CUL3) 
226521_s_at 1.5128 0.0144 FAM175A double-strand break 
repairvia (FAM175A) 
228333_at 1.3747 0.0145 ZEB2 zinc finger E-box binding homeobox 
2 (ZEB2) 
1558080_s_at -3.8846 0.0146 DNAJC3 DnaJ heat shock protein family 
(Hsp40) member C3 (DNAJC3) 
219067_s_at 1.9095 0.0146 NSMCE4A NSE4 homolog A, SMC5-SMC6 
complex component (NSMCE4A) 
52731_at -1.4557 0.0146 AMBRA1 autophagy and beclin 1 regulator 1 
(AMBRA1) 
1561615_s_at 2.3000 0.0146 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
208010_s_at -1.5750 0.0147 PTPN22 protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) 
222807_at 1.2302 0.0147 EMSY EMSY, BRCA2 interacting 
transcriptional repressor (EMSY) 
200934_at 1.4911 0.0148 DEK DEK proto-oncogene (DEK) 
230006_s_at 2.6796 0.0148 SVIP small VCP interacting protein (SVIP) 
204023_at 1.7144 0.0150 RFC4 replication factor C subunit 4 (RFC4) 
223493_at 1.8467 0.0152 FBXO4 F-box protein 4 (FBXO4) 
1553906_s_at 1.2276 0.0153 FGD2 FYVE, RhoGEF and PH domain 
containing 2 (FGD2) 
209054_s_at 1.3526 0.0153 NSD2 uclear receptor binding SET domain 
protein 2 (NSD2) 
225696_at 1.6972 0.0153 COPS7B COP9 signalosome subunit 7B 
(COPS7B) 
229331_at 1.9833 0.0155 SPATA18 spermatogenesis associated 18 
(SPATA18) 
203160_s_at 1.1469 0.0155 RNF8 ring finger protein 8 (RNF8) 
39402_at 1.8860 0.0156 IL1B interleukin 1 beta (IL1B) 
202105_at 1.2921 0.0158 IGBP1 immunoglobulin (CD79A) binding 
protein 1 (IGBP1) 
202911_at 1.3034 0.0158 MSH6 mutS homolog 6 (MSH6) 
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205483_s_at 1.6765 0.0160 ISG15 ISG15 ubiquitin-like modifier (ISG15) 
204418_x_at -1.0380 0.0161 GSTM2 glutathione S-transferase mu 2 
(GSTM2) 
204418_x_at -1.0380 0.0161 GSTM1 glutathione S-transferase mu 1 
(GSTM1) 
202842_s_at -1.2740 0.0162 DNAJB9 DnaJ heat shock protein family 
(Hsp40) member B9 (DNAJB9) 
202763_at 1.1677 0.0162 CASP3 caspase 3 (CASP3) 
220160_s_at 1.0558 0.0163 KPTN kaptin, actin binding protein (KPTN) 
209310_s_at 1.3873 0.0163 CASP4 caspase 4 (CASP4) 
225097_at -1.7557 0.0164 HIPK2 homeodomain interacting protein 
kinase 2 (HIPK2) 
242281_at 2.5947 0.0164 GLUL glutamate-ammonia ligase (GLUL) 
230108_at 2.3364 0.0165 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
203022_at 1.3706 0.0165 RNASEH2A ribonuclease H2 subunit A 
(RNASEH2A) 
211323_s_at -2.0472 0.0168 ITPR1 inositol 1,4,5-trisphosphate receptor 
type 1 (ITPR1) 
201746_at 1.7735 0.0169 TP53 tumor protein p53 (TP53) 
221931_s_at 1.0832 0.0170 SEH1L SEH1 like nucleoporin (SEH1L) 
204622_x_at 3.4868 0.0170 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
226048_at 1.1930 0.0170 MAPK8 mitogen-activated protein kinase 8 
(MAPK8) 
1558938_at 3.0766 0.0171 PSME1 proteasome activator subunit 1 
(PSME1) 
224591_at 1.0505 0.0173 HP1BP3 heterochromatin protein 1 binding 
protein 3 (HP1BP3) 
203171_s_at 1.0212 0.0176 RRP8 ribosomal RNA processing 8, 
methyltransferase, homolog (yeast) 
(RRP8) 
205672_at 1.3707 0.0176 XPA XPA, DNA damage recognition and 
repair factor (XPA) 
202431_s_at 1.1770 0.0176 MYC v-myc avian myelocytomatosis viral 
oncogene homolog (MYC) 
202073_at 1.1093 0.0177 OPTN Optineurin (OPTN) 
219215_s_at 1.6048 0.0177 SLC39A4 solute carrier family 39 member 4 
(SLC39A4) 
203526_s_at -1.8957 0.0179 APC APC, WNT signaling pathway 
regulator (APC) 
33322_i_at -1.3740 0.0179 SFN Stratifin (SFN) 
235754_at -2.2089 0.0179 HFE Hemochromatosis (HFE) 
201053_s_at 1.1670 0.0181 PSMF1 proteasome inhibitor subunit 1 
(PSMF1) 
209349_at -1.5863 0.0182 RAD50 RAD50 double strand break repair 
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protein (RAD50) 
1552329_at 2.6277 0.0183 RBBP6 RB binding protein 6, ubiquitin ligase 
(RBBP6) 
203315_at 1.1304 0.0185 NCK2 NCK adaptor protein 2 (NCK2) 
1560017_at -1.0583 0.0185 TMTC3 transmembrane and 
tetratricopeptide repeat containing 3 
(TMTC3) 
208436_s_at 1.7210 0.0189 IRF7 interferon regulatory factor 7 (IRF7) 
204748_at 1.9749 0.0191 PTGS2 prostaglandin-endoperoxide 
synthase 2 (PTGS2) 
241425_at -2.7343 0.0191 NUP58 nucleoporin 58(NUP58) 
216241_s_at 1.2579 0.0193 TCEA1 transcription elongation factor A1 
(TCEA1) 
223159_s_at 1.1422 0.0193 NEK6 NIMA related kinase 6 (NEK6) 
205047_s_at 2.2915 0.0193 ASNS asparagine synthetase (glutamine-
hydrolyzing )(ASNS) 
203616_at 1.2997 0.0194 POLB DNA polymerase beta (POLB) 
244428_at 1.8192 0.0195 DNMT3A DNA methyltransferase 3 alpha 
(DNMT3A) 
222646_s_at -1.7167 0.0197 ERO1A endoplasmic reticulum 
oxidoreductase 1 alpha (ERO1A) 
212018_s_at 1.0291 0.0198 RSL1D1 ribosomal L1 domain containing 1 
(RSL1D1) 
214246_x_at 1.9165 0.0198 MINK1 misshapen like kinase 1 (MINK1) 
206976_s_at -1.1303 0.0199 HSPH1 heat shock protein family H (Hsp110) 
member 1 (HSPH1) 
230300_at 2.8703 0.0202 PSMA5 proteasome subunit alpha 5 (PSMA5) 
209824_s_at 1.3400 0.0207 ARNTL aryl hydrocarbon receptor nuclear 
translocator like (ARNTL) 
219383_at 2.9946 0.0210 PRR5L proline rich 5 like (PRR5L) 
213596_at 2.3761 0.0210 CASP4 caspase 4 (CASP4) 
235749_at -1.8402 0.0210 UGGT2 UDP-glucose glycoprotein 
glucosyltransferase 2 (UGGT2) 
219334_s_at -1.4848 0.0211 NABP1 nucleic acid binding protein 
1(NABP1) 
228109_at 1.8172 0.0212 RASGRF2 Ras protein specific guanine 
nucleotide releasing factor 2 
(RASGRF2) 
203607_at 1.7497 0.0213 INPP5F inositol polyphosphate-5-
phosphatase F (INPP5F) 
223879_s_at -2.6287 0.0213 OXR1 oxidation resistance 1 (OXR1) 
209743_s_at -1.3636 0.0213 ITCH itchy E3 ubiquitin protein ligase 
(ITCH) 
202244_at 1.0216 0.0216 PSMB4 proteasome subunit beta 4 (PSMB4) 
210480_s_at -2.2763 0.0216 MYO6 myosin VI (MYO6) 
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56919_at 1.8901 0.0217 WDR48 WD repeat domain 48 (WDR48) 
217736_s_at 1.0525 0.0217 EIF2AK1 eukaryotic translation initiation 
factor 2 alpha kinase 1 (EIF2AK1) 
202062_s_at -4.7666 0.0217 SEL1L SEL1L ERAD E3 ligase adaptor subunit 
(SEL1L) 
242300_at 2.2163 0.0218 UBB ubiquitin B (UBB) 
207805_s_at 1.1013 0.0218 PSMD9 proteasome 26S subunit, non-ATPase 
9 (PSMD9) 
205126_at 1.1141 0.0220 VRK2 vaccinia related kinase 2 (VRK2) 
214953_s_at -2.8294 0.0220 APP amyloid beta precursor protein (APP) 
213734_at -1.2283 0.0223 RFC5 replication factor C subunit 5 (RFC5) 
209418_s_at -1.1521 0.0225 THOC5 THO complex 5 (THOC5) 
219028_at -1.2784 0.0227 HIPK2 homeodomain interacting protein 
kinase 2 (HIPK2) 
202494_at 1.1265 0.0227 PPIE peptidylprolyl isomerase E (PPIE) 
209615_s_at 1.4380 0.0229 PAK1 p21 (RAC1) activated kinase 1(PAK1) 
218346_s_at 1.1288 0.0230 SESN1 sestrin 1 (SESN1) 
204672_s_at -1.1542 0.0232 ANKRD6 ankyrin repeat domain 6 (ANKRD6) 
221477_s_at 1.1698 0.0232 SOD2 superoxide dismutase 2, 
mitochondrial (SOD2) 
218689_at 2.2123 0.0235 FANCF Fanconi anemia complementation 
group F (FANCF) 
203427_at 1.6082 0.0235 ASF1A anti-silencing function 1A histone 
chaperone (ASF1A) 
203988_s_at 1.7889 0.0235 FUT8 fucosyltransferase 8 (FUT8) 
204203_at 1.2073 0.0236 CEBPG CCAAT/enhancer binding protein 
gamma (CEBPG) 
225115_at -1.7948 0.0238 HIPK2 homeodomain interacting protein 
kinase 2 (HIPK2) 
238813_at 1.5429 0.0238 APEX2 apurinic/apyrimidinic 
endodeoxyribonuclease 2 (APEX2) 
219141_s_at -1.0916 0.0243 AMBRA1 autophagy and beclin 1 regulator 1 
(AMBRA1) 
211376_s_at 1.9920 0.0246 NSMCE4A NSE4 homolog A, SMC5-SMC6 
complex component (NSMCE4A) 
228506_at 1.9407 0.0247 NSMCE4A NSE4 homolog A, SMC5-SMC6 
complex component (NSMCE4A) 
215416_s_at 2.1026 0.0250 STOML2 stomatin like 2 (STOML2) 
221841_s_at 1.7739 0.0254 KLF4 Kruppel like factor 4 (KLF4) 
228183_s_at 1.1745 0.0254 RPAIN RPA interacting protein (RPAIN) 
229010_at 1.4328 0.0262 CBL Cbl proto-oncogene (CBL) 
201404_x_at -1.0653 0.0262 PSMB2 proteasome subunit beta 3 (PSMB3) 
201391_at 1.1342 0.0264 TRAP1 TNF receptor associated protein 1 
(TRAP1) 
204961_s_at 3.3847 0.0264 NCF1 neutrophil cytosolic factor 1 (NCF1) 
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204617_s_at 1.7673 0.0265 ACD adrenocortical dysplasia homolog 
(ACD) 
225651_at 1.2655 0.0265 UBE2E2 ubiquitin conjugating enzyme E2 E2 
(UBE2E2) 
222909_s_at 1.3891 0.0266 BAG4 BCL2 associated athanogene 4 
(BAG4) 
200602_at -2.0802 0.0266 APP amyloid beta precursor protein (APP) 
210257_x_at -1.1531 0.0267 CUL4B cullin 4B (CUL4B) 
218671_s_at 1.1264 0.0268 ATPIF1 ATPase inhibitory factor 1 (ATPIF1) 
221253_s_at -1.1705 0.0271 TXNDC5 thioredoxin domain containing 5 
(TXNDC5) 
210354_at 3.4520 0.0271 IFNG interferon gamma (IFNG) 
201222_s_at -1.4846 0.0273 RAD23B RAD23 homolog B, nucleotide 
excision repair protein (RAD23B) 
211832_s_at -1.7581 0.0273 MDM2 MDM2 proto-oncogene (MDM2) 
212331_at 1.0703 0.0274 RBL2 RB transcriptional corepressor like 2 
(RBL2) 
218878_s_at 1.5020 0.0275 SIRT1 sirtuin 1 (SIRT1) 
213170_at 2.3971 0.0275 GPX7 glutathione peroxidase 7 (GPX7) 
218340_s_at -1.7507 0.0275 UBA6 ubiquitin like modifier activating 
enzyme 6 (UBA6) 
240413_at 2.2689 0.0277 PYHIN1 pyrin and HIN domain family 
member 1 (PYHIN1) 
201631_s_at 1.3549 0.0281 IER3 immediate early response 3 (IER3) 
227628_at -1.1972 0.0283 GPX8 glutathione peroxidase 8 (putative) 
(GPX8) 
203527_s_at -1.5834 0.0284 APC APC, WNT signaling pathway 
regulator (APC) 
212252_at 1.0645 0.0284 CAMKK2 calcium/calmodulin dependent 
protein kinase kinase 2 (CAMKK2) 
225470_at 2.4713 0.0288 NUP35 nucleoporin 35 (NUP35) 
233019_at 1.1693 0.0288 CNOT7 CCR4-NOT transcription complex 
subunit 7 (CNOT7) 
203588_s_at 1.5842 0.0289 TFDP2 transcription factor Dp-2 (TFDP2) 
203103_s_at 1.3563 0.0291 PRPF19 pre-mRNA processing factor 19 
(PRPF19) 
227119_at 1.2457 0.0292 CNOT6L CCR4-NOT transcription complex 
subunit 6 like (CNOT6L) 
218463_s_at 1.0056 0.0294 MUS81 MUS81 structure-specific 
endonuclease subunit (MUS81) 
200889_s_at -1.2155 0.0300 SSR1 signal sequence receptor subunit 1 
(SSR1) 
214843_s_at -1.1260 0.0304 USP33 ubiquitin specific peptidase 33 
(USP33) 
226008_at 1.1566 0.0307 NSMCE3 NSE3 homolog, SMC5-SMC6 complex 
component (NSMCE3) 
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1553096_s_at 1.1773 0.0309 BCL2L11 BCL2 like 11 (BCL2L11) 
200880_at 1.0309 0.0309 DNAJA1 DnaJ heat shock protein family 
(Hsp40) member A1 (DNAJA1) 
232206_at -1.8102 0.0309 ULK4 unc-51 like kinase 4 (ULK4) 
1554251_at 1.8315 0.0311 HP1BP3 heterochromatin protein 1 binding 
protein  3(HP1BP3) 
219578_s_at -3.2788 0.0311 CPEB1 cytoplasmic polyadenylation element 
binding protein 1 (CPEB1) 
229141_at 1.9646 0.0312 WDR33 WD repeat domain 33 (WDR33) 
207727_s_at 1.0357 0.0312 MUTYH mutY DNA glycosylase (MUTYH) 
227143_s_at 1.1127 0.0312 BID BH3 interacting domain death 
agonist (BID) 
225923_at 1.4085 0.0313 VAPB VAMP associated protein B and  C 
(VAPB) 
31874_at 1.0400 0.0314 GAS2L1 growth arrest specific 2 like 
1( GAS2L1) 
203577_at 1.1988 0.0319 GTF2H4 general transcription factor IIH 
subunit 4 (GTF2H4) 
203358_s_at 3.1157 0.0320 EZH2 enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) 
212749_s_at 1.4305 0.0321 RCHY1 ring finger and CHY zinc finger 
domain containing 1 (RCHY1) 
239810_at 1.2337 0.0322 VASH1 vasohibin 1 (VASH1) 
203805_s_at 1.2728 0.0323 FANCA Fanconi anemia complementation 
group A (FANCA) 
202843_at -1.5760 0.0325 DNAJB9 DnaJ heat shock protein family 
(Hsp40) member B9 (DNAJB9) 
204832_s_at -1.5563 0.0332 BMPR1A bone morphogenetic protein 
receptor type 1A (BMPR1A) 
225116_at -2.4597 0.0332 HIPK2 homeodomain interacting protein 
kinase 2 (HIPK2) 
234362_s_at 2.4117 0.0333 CTLA4 cytotoxic T-lymphocyte associated 
protein 4 (CTLA4) 
222343_at 1.1843 0.0334 BCL2L11 BCL2 like 11 (BCL2L11) 
227027_at -1.0695 0.0337 GFPT1 glutamine--fructose-6-phosphate 
transaminase 1 (GFPT1) 
205081_at 2.3734 0.0340 CRIP1 cysteine rich protein 1 (CRIP1) 
202638_s_at 1.7367 0.0343 ICAM1 intercellular adhesion molecule 1 
(ICAM1) 
201211_s_at -1.0638 0.0345 DDX3X DEAD-box helicase 3, X-linked 
(DDX3X) 
235850_at 1.5725 0.0351 FAM162A family with sequence similarity 162 
member A (FAM162A) 
202625_at 1.3497 0.0352 LYN LYN proto-oncogene, Src family 
tyrosine kinase (LYN) 
202401_s_at 1.0717 0.0355 SRF serum response factor(SRF) 
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200758_s_at -1.2326 0.0357 NFE2L1 nuclear factor, erythroid 2 like 1 
(NFE2L1) 
203817_at 1.9985 0.0358 GUCY1B3 guanylate cyclase 1 soluble subunit 
beta (GUCY1B3) 
235341_at -2.9540 0.0359 DNAJC3 DnaJ heat shock protein family 
(Hsp40) member C3 (DNAJC3) 
217735_s_at 1.3169 0.0359 EIF2AK1 eukaryotic translation initiation 
factor 2 alpha kinase 1 (EIF2AK1) 
213007_at 1.1502 0.0360 FANCI Fanconi anemia complementation 
group I (FANCI) 
213750_at 1.7795 0.0367 RSL1D1 ribosomal L1 domain containing 1 
(RSL1D1) 
202412_s_at 1.9167 0.0368 USP1 ubiquitin specific peptidase 1 (USP1) 
206665_s_at -1.8977 0.0369 BCL2L1 BCL2 like 1 (BCL2L1) 
201316_at 1.6425 0.0370 PSMA2 proteasome subunit alpha 2 (PSMA2) 
223275_at 2.4144 0.0375 PRMT6 protein arginine methyltransferase 6 
(PRMT6) 
205067_at 2.1878 0.0380 IL1B interleukin 1 beta (IL1B) 
207039_at 2.2441 0.0380 CDKN2A cyclin dependent kinase inhibitor 2A 
(CDKN2A) 
225824_at 1.3895 0.0382 CCNK cyclin K (CCNK) 
217127_at -1.7073 0.0385 CTH cystathionine gamma-lyase (CTH) 
211595_s_at 1.0919 0.0386 MRPS11 mitochondrial ribosomal protein S11 
(MRPS11) 
224792_at -2.2003 0.0389 TNKS1BP1 tankyrase 1 binding protein 1 
(TNKS1BP1) 
221830_at -2.3497 0.0392 RAP2A RAP2A, member of RAS oncogene 
family (RAP2A) 
229720_at 1.1039 0.0392 BAG1 BCL2 associated athanogene 1 
(BAG1) 
223960_s_at 1.0203 0.0394 CDIP1 cell death inducing p53 target 1 
(CDIP1) 
212751_at 1.1923 0.0395 UBE2N ubiquitin conjugating enzyme E2 N 
(UBE2N) 
209456_s_at -2.3494 0.0396 FBXW11 F-box and WD repeat domain 
containing 11 (FBXW11) 
208692_at 1.4602 0.0397 RPS3 ribosomal protein S3 (RPS3) 
207108_s_at -1.9856 0.0398 NIPBL NIPBL, cohesin loading factor (NIPBL) 
215533_s_at -1.9690 0.0399 UBE4B ubiquitination factor E4B (UBE4B) 
201002_s_at 1.2194 0.0400 UBE2V1 ubiquitin conjugating enzyme E2 V1 
(UBE2V1) 
205909_at 2.1843 0.0408 POLE2 DNA polymerase epsilon 2, accessory 
subunit (POLE2) 
220066_at 1.9755 0.0408 NOD2 nucleotide binding oligomerization 
domain containing 2 (NOD2) 
209511_at 1.1086 0.0408 POLR2F RNA polymerase II subunit F 
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(POLR2F) 
221331_x_at 1.8292 0.0409 CTLA4 cytotoxic T-lymphocyte associated 
protein 4 (CTLA4) 
203216_s_at -1.1468 0.0410 MYO6 myosin VI (MYO6) 
223339_at 2.3401 0.0412 ATPIF1 ATPase inhibitory factor 1 (ATPIF1) 
38290_at 1.0282 0.0419 RGS14 regulator of G-protein signaling 14 
(RGS14) 
225836_s_at 1.8093 0.0420 RHNO1 RAD9-HUS1-RAD1 interacting nuclear 
orphan 1 (RHNO1) 
204131_s_at -2.0174 0.0421 FOXO3 forkhead box O3 (FOXO3) 
205811_at 1.3020 0.0424 POLG2 DNA polymerase gamma 2, accessory 
subunit (POLG2) 
227678_at 1.1093 0.0424 ATP23 ATP23 metallopeptidase and ATP 
synthase assembly factor homolog 
(ATP23) 
213136_at 1.2147 0.0425 PTPN2 protein tyrosine phosphatase, non-
receptor type 2 (PTPN2) 
225589_at -1.0881 0.0429 SH3RF1 SH3 domain containing ring finger 1 
(SH3RF1) 
232287_at 2.7107 0.0429 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
211506_s_at -4.1043 0.0432 CXCL8 C-X-C motif chemokine ligand 8 
(CXCL8) 
202466_at 1.1560 0.0433 PAPD7 poly(A) RNA polymerase D7, non-
canonical (PAPD7) 
218499_at 1.6223 0.0434 STK26 serine/threonine protein kinase 26 
(STK26) 
211863_x_at -1.0014 0.0434 HFE Hemochromatosis (HFE) 
230192_at 1.2646 0.0436 TRIM13 tripartite motif containing 13 
(TRIM13) 
204621_s_at 2.0158 0.0436 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
208948_s_at 1.1438 0.0438 STAU1 staufen double-stranded RNA 
binding protein 1 (STAU1) 
226022_at -1.1266 0.0438 SASH1 SAM and SH3 domain containing 1 
(SASH1) 
204824_at 1.0160 0.0438 ENDOG endonuclease G (ENDOG) 
235609_at 2.3943 0.0443 BRIP1 BRCA1 interacting protein C-terminal 
helicase 1 (BRIP1) 
225144_at -1.0022 0.0443 BMPR2 bone morphogenetic protein 
receptor type 2 (BMPR2) 
212927_at 1.2228 0.0450 SMC5 structural maintenance of 
chromosomes 5 (SMC5) 
220342_x_at -1.7405 0.0463 EDEM3 ER degradation enhancing alpha-
mannosidase like protein 3 (EDEM3) 
1554411_at -4.2264 0.0466 CTNNB1 catenin beta 1(CTNNB1) 
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209994_s_at -1.0281 0.0468 ABCB4 ATP binding cassette subfamily B 
member 4 (ABCB4) 
243000_at 1.8848 0.0469 CDK6 cyclin dependent kinase 6 (CDK6) 
226939_at -1.0229 0.0474 CPEB2 cytoplasmic polyadenylation element 
binding protein 2 (CPEB2) 
231873_at -1.1004 0.0479 BMPR2 bone morphogenetic protein 
receptor type 2 (BMPR2) 
228925_at 1.4197 0.0480 MAPKAPK
5 
mitogen-activated protein kinase-
activated protein kinase 5 
(MAPKAPK5) 
213357_at 1.1921 0.0480 GTF2H5 general transcription factor IIH 
subunit 5 (GTF2H5) 
201502_s_at 1.4184 0.0480 NFKBIA NFKB inhibitor alpha (NFKBIA) 
218608_at -4.2617 0.0480 ATP13A2 ATPase 13A2 (ATP13A2) 
201115_at 1.1993 0.0485 POLD2 DNA polymerase delta 2, accessory 
subunit (POLD2) 
200764_s_at -1.0486 0.0485 CTNNA1 catenin alpha 1 (CTNNA1) 
202859_x_at -1.6208 0.0486 CXCL8 C-X-C motif chemokine ligand 8 
(CXCL8) 
     
 
 
COPD 
Affy probe ID logFC q value Name Gene name 
213931_at -1.6783 0.0002 ID2 inhibitor of DNA binding 2, HLH 
protein (ID2) 
203234_at 1.3446 0.0148 UPP1 uridine phosphorylase 1 (UPP1) 
227073_at -1.1097 0.0155 MAP3K2 mitogen-activated protein kinase 
kinase kinase 2 (MAP3K2) 
200632_s_at 1.4802 0.0162 NDRG1 N-myc downstream regulated 1 
(NDRG1) 
225207_at -1.7186 0.0162 PDK4 pyruvate dehydrogenase kinase 4 
(PDK4) 
236539_at -1.0176 0.0200 PTPN22 protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) 
203379_at 1.0091 0.0200 RPS6KA1 ribosomal protein S6 kinase A1 
(RPS6KA1) 
242669_at -1.2042 0.0222 UFM1 ubiquitin fold modifier 1 (UFM1) 
214048_at -1.0364 0.0247 MBD4 methyl-CpG binding domain 4, DNA 
glycosylase (MBD4) 
221768_at -1.4014 0.0254 SFPQ splicing factor proline and glutamine 
rich (SFPQ) 
242300_at 1.3782 0.0292 UBB ubiquitin B (UBB) 
200895_s_at 1.0642 0.0296 FKBP4 FK506 binding protein 4 (FKBP4) 
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203315_at 1.9792 0.0319 NCK2 NCK adaptor protein 2 (NCK2) 
241752_at -1.0278 0.0319 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
201565_s_at -1.1118 0.0328 ID2 inhibitor of DNA binding 2, HLH 
protein (ID2) 
202393_s_at -1.0453 0.0329 KLF10 Kruppel like factor 10 (KLF10) 
215037_s_at 1.5925 0.0330 BCL2L1 BCL2 like 1 (BCL2L1) 
229221_at -1.0147 0.0333 CD44 CD44 molecule (Indian blood group) 
(CD44) 
228506_at -1.2858 0.0341 NSMCE4A NSE4 homolog A, SMC5-SMC6 
complex component (NSMCE4A) 
202073_at 1.1746 0.0360 OPTN Optineurin (OPTN) 
202539_s_at -2.1819 0.0362 HMGCR 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR) 
201848_s_at 1.8162 0.0366 BNIP3 BCL2 interacting protein 3 (BNIP3) 
218801_at -1.0358 0.0369 UGGT2 UDP-glucose glycoprotein 
glucosyltransferase 2 (UGGT2) 
243751_at -1.1260 0.0399 CHD2 chromodomain helicase DNA binding 
protein 2 (CHD2) 
1556583_a_at -1.1444 0.0399 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
201626_at -1.5651 0.0423 INSIG1 insulin induced gene 1 (INSIG1) 
207540_s_at 1.0715 0.0459 SYK spleen associated tyrosine kinase 
(SYK) 
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Table E4 Differentially regulated gene probes belonging to GO term Oxidative 
Stress 
 
Healthy 
Affy probe ID logFC q value Name Gene Name 
204639_at 2.4216 0.0136 ADA adenosine deaminase(ADA) 
202381_at -1.1223 0.0147 ADAM9 ADAM metallopeptidase domain 9 
(ADAM9) 
203322_at 1.4707 0.0095 ADNP2 ADNP homeobox  2(ADNP2) 
209901_x_at 2.1444 0.0055 AIF1 allograft inflammatory factor 1 (AIF1) 
213095_x_at 2.0801 0.0046 AIF1 allograft inflammatory factor 1 (AIF1) 
215051_x_at 1.8362 0.0058 AIF1 allograft inflammatory factor 1 (AIF1) 
201272_at -1.4230 0.0039 AKR1B1 aldo-keto reductase family 1 
member B (AKR1B1) 
226291_at -1.1426 0.0069 ALS2 ALS2, alsin Rho guanine nucleotide 
exchange factor (ALS2) 
200602_at -2.0802 0.0266 APP amyloid beta precursor protein (APP) 
214953_s_at -2.8294 0.0220 APP amyloid beta precursor protein (APP) 
209824_s_at 1.3400 0.0207 ARNTL aryl hydrocarbon receptor nuclear 
translocator like (ARNTL) 
203454_s_at 1.5541 0.0018 ATOX1 antioxidant 1 copper chaperone 
(ATOX1) 
218608_at -4.2617 0.0480 ATP13A2 ATPase 13A2(ATP13A2) 
205197_s_at -4.3706 0.0016 ATP7A ATPase copper transporting alpha 
(ATP7A) 
212517_at -1.3649 0.0348 ATRN Attractin (ATRN) 
212252_at 1.0645 0.0284 CAMKK2 calcium/calmodulin dependent 
protein kinase kinase 2 (CAMKK2) 
202763_at 1.1677 0.0162 CASP3 caspase 3 (CASP3) 
203418_at 3.2141 0.0029 CCNA2 cyclin A2 (CCNA2) 
213226_at 2.8150 0.0045 CCNA2 cyclin A2 (CCNA2) 
206488_s_at -2.1956 0.0014 CD36 CD36 molecule (CD36) 
209555_s_at -2.4553 0.0015 CD36 CD36 molecule (CD36) 
228766_at -2.2228 0.0036 CD36 CD36 molecule (CD36) 
242197_x_at -1.6963 0.0104 CD36 CD36 molecule (CD36) 
205692_s_at 3.4131 0.0006 CD38 CD38 molecule (CD38) 
203213_at 4.7116 0.0059 CDK1 cyclin dependent kinase 1 (CDK1) 
203214_x_at 3.8980 0.0032 CDK1 cyclin dependent kinase 1 (CDK1) 
226939_at -1.0229 0.0474 CPEB2 cytoplasmic polyadenylation element 
binding protein 2 (CPEB2) 
1554411_at -4.2264 0.0466 CTNNB1 catenin beta 1(CTNNB1) 
226632_at -1.5163 0.0099 CYGB Cytoglobin (CYGB) 
204824_at 1.0160 0.0438 ENDOG endonuclease G (ENDOG) 
200878_at -1.6743 0.0009 EPAS1 endothelial PAS domain protein 1 
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(EPAS1) 
200879_s_at -3.4515 0.0025 EPAS1 endothelial PAS domain protein 1 
(EPAS1) 
203719_at 1.3789 0.0094 ERCC1 ERCC excision repair 1, endonuclease 
non-catalytic subunit (ERCC1) 
207347_at 2.6408 0.0035 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
230108_at 2.3364 0.0165 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
232287_at 2.7107 0.0429 ERCC6 ERCC excision repair 6, chromatin 
remodeling factor (ERCC6) 
218498_s_at -1.4255 0.0142 ERO1A endoplasmic reticulum 
oxidoreductase 1 alpha (ERO1A) 
222646_s_at -1.7167 0.0197 ERO1A endoplasmic reticulum 
oxidoreductase 1 alpha (ERO1A) 
224833_at 4.4827 0.0015 ETS1 ETS proto-oncogene 1, transcription 
factor (ETS1) 
203358_s_at 3.1157 0.0320 EZH2 enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) 
232064_at -1.1974 0.0050 FER FER tyrosine kinase (FER) 
202724_s_at 1.5573 0.0055 FOXO1 forkhead box O1 (FOXO1) 
204131_s_at -2.0174 0.0421 FOXO3 forkhead box O3 (FOXO3) 
203988_s_at 1.7889 0.0235 FUT8 fucosyltransferase 8 (FUT8) 
204224_s_at 5.3079 0.0008 GCH1 GTP cyclohydrolase 1 (GCH1) 
202922_at 1.2872 0.0040 GCLC glutamate-cysteine ligase catalytic 
subunit (GCLC) 
202923_s_at 1.2349 0.0027 GCLC glutamate-cysteine ligase catalytic 
subunit (GCLC) 
223278_at 3.0753 0.0030 GJB2 gap junction protein beta 2 (GJB2) 
213170_at 2.3971 0.0275 GPX7 glutathione peroxidase 7 (GPX7) 
227628_at -1.1972 0.0283 GPX8 glutathione peroxidase 8 (putative) 
(GPX8) 
203817_at 1.9985 0.0358 GUCY1B3 guanylate cyclase 1 soluble subunit 
beta (GUCY1B3) 
206976_s_at -1.1303 0.0199 HSPH1 heat shock protein family H (Hsp110) 
member 1 (HSPH1) 
208744_x_at -1.5729 0.0134 HSPH1 heat shock protein family H (Hsp110) 
member 1 (HSPH1) 
207072_at 3.6333 0.0020 IL18RAP interleukin 18 receptor accessory 
protein (IL18RAP) 
221841_s_at 1.7739 0.0254 KLF4 Kruppel like factor 4 (KLF4) 
209653_at -1.0706 0.0064 KPNA4 karyopherin subunit alpha 4 (KPNA4) 
1552263_at 2.1817 0.0057 MAPK1 mitogen-activated protein kinase 1 
(MAPK1) 
226048_at 1.1930 0.0170 MAPK8 mitogen-activated protein kinase 8 
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(MAPK8) 
200797_s_at 1.4190 0.0029 MCL1 BCL2 family apoptosis regulator 
(MCL1) 
200798_x_at 1.4244 0.0055 MCL1 BCL2 family apoptosis regulator 
(MCL1) 
205386_s_at -1.6688 0.0128 MDM2 MDM2 proto-oncogene (MDM2) 
211832_s_at -1.7581 0.0273 MDM2 MDM2 proto-oncogene (MDM2) 
217373_x_at -1.5002 0.0018 MDM2 MDM2 proto-oncogene (MDM2) 
225160_x_at -3.3167 0.0041 MDM2 MDM2 proto-oncogene (MDM2) 
203510_at -4.5338 0.0016 MET MET proto-oncogene, receptor 
tyrosine kinase (MET) 
1565162_s_at -1.5077 0.0065 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
224918_x_at -1.0379 0.0042 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
231736_x_at -1.0800 0.0033 MGST1 microsomal glutathione S-
transferase 1 (MGST1) 
205905_s_at -2.3166 0.0022 MICB MHC class I polypeptide-related 
sequence B (MICB) 
228528_at 1.4066 0.0059 MIR29B2 microRNA 29b-2 (MIR29B2) 
204798_at 4.2929 0.0052 MYB MYB proto-oncogene, transcription 
factor (MYB) 
204961_s_at 3.3847 0.0264 NCF1 neutrophil cytosolic factor 1 (NCF1) 
214084_x_at 2.9014 0.0054 NCF1 neutrophil cytosolic factor 1 (NCF1) 
225344_at 1.3596 0.0068 NCOA7 nuclear receptor coactivator 7 
(NCOA7) 
223244_s_at 1.4173 0.0086 NDUFA12 NADH:ubiquinone oxidoreductase 
subunit A12 (NDUFA12) 
203190_at 1.1449 0.0072 NDUFS8 NADH:ubiquinone oxidoreductase 
core subunit S8 (NDUFS8) 
201829_at 2.3673 0.0053 NET1 neuroepithelial cell transforming 1 
(NET1) 
201830_s_at 3.1156 0.0029 NET1 neuroepithelial cell transforming 1 
(NET1) 
200758_s_at -1.2326 0.0357 NFE2L1 nuclear factor, erythroid 2 like 1 
(NFE2L1) 
220384_at 3.4506 0.0016 NME8 NME/NM23 family member 8 
(NME8) 
204621_s_at 2.0158 0.0436 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
204622_x_at 3.4868 0.0170 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
216248_s_at 3.3321 0.0142 NR4A2 nuclear receptor subfamily 4 group A 
member 2 (NR4A2) 
209959_at 6.1518 0.0014 NR4A3 nuclear receptor subfamily 4 group A 
member 3 (NR4A3) 
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218609_s_at 1.9037 0.0048 NUDT2 nudix hydrolase 2 (NUDT2) 
218197_s_at -1.8142 0.0018 OXR1 oxidation resistance 1 (OXR1) 
223879_s_at -2.6287 0.0213 OXR1 oxidation resistance 1 (OXR1) 
201202_at 2.0012 0.0054 PCNA proliferating cell nuclear antigen 
(PCNA) 
206686_at -1.6488 0.0086 PDK1 pyruvate dehydrogenase kinase 1 
(PDK1) 
201489_at 1.2158 0.0081 PPIF peptidylprolyl isomerase F (PPIF) 
242751_at -1.6397 0.0103 PRDX6 peroxiredoxin 6 (PRDX6) 
209139_s_at 1.3821 0.0102 PRKRA protein activator of interferon 
induced protein kinase EIF2AK2 
(PRKRA) 
219383_at 2.9946 0.0210 PRR5L proline rich 5 like (PRR5L) 
203460_s_at -1.0503 0.0031 PSEN1 presenilin 1 (PSEN1) 
205961_s_at 4.2381 0.0034 PSIP1 PC4 and SFRS1 interacting protein 1 
(PSIP1) 
209337_at 4.3718 0.0027 PSIP1 PC4 and SFRS1 interacting protein 1 
(PSIP1) 
204748_at 1.9749 0.0191 PTGS2 prostaglandin-endoperoxide 
synthase 2 (PTGS2) 
200651_at 1.3886 0.0082 RACK1 receptor for activated C kinase 1 
(RACK1) 
38290_at 1.0282 0.0419 RGS14 regulator of G-protein signaling 14 
(RGS14) 
212099_at 2.9696 0.0087 RHOB ras homolog family member B 
(RHOB) 
224972_at 1.3415 0.0137 ROMO1 reactive oxygen species modulator 1 
(ROMO1) 
208692_at 1.4602 0.0397 RPS3 ribosomal protein S3 (RPS3) 
201286_at -1.4633 0.0052 SDC1 syndecan 1 (SDC1) 
201287_s_at -2.5360 0.0010 SDC1 sestrin 1 (SESN1) 
218346_s_at 1.1288 0.0230 SESN1 sestrin 3(SESN3) 
225123_at 2.7206 0.0093 SESN3 SIN3 transcription regulator family 
member A (SIN3A) 
225135_at 2.7524 0.0046 SIN3A SIN3 transcription regulator family 
member A (SIN3A) 
238005_s_at 1.9612 0.0047 SIN3A SIN3 transcription regulator family 
member A (SIN3A) 
218878_s_at 1.5020 0.0275 SIRT1 sirtuin 1 (SIRT1) 
211572_s_at -2.1236 0.0015 SLC23A2 solute carrier family 23 member 2 
(SLC23A2) 
209921_at 3.3825 0.0026 SLC7A11 solute carrier family 7 member 11 
(SLC7A11) 
217678_at 4.4084 0.0092 SLC7A11 solute carrier family 7 member 11 
(SLC7A11) 
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1561615_s_at 2.3000 0.0146 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
204466_s_at -5.0755 0.0011 SNCA synuclein alpha (SNCA) 
204467_s_at -2.2398 0.0041 SNCA synuclein alpha (SNCA) 
207827_x_at -4.1027 0.0030 SNCA synuclein alpha (SNCA) 
211546_x_at -3.0292 0.0041 SNCA synuclein alpha(SNCA) 
200642_at 1.1138 0.0033 SOD1 superoxide dismutase 1, soluble 
(SOD1) 
215223_s_at 2.2428 0.0019 SOD2 superoxide dismutase 2, 
mitochondrial (SOD2) 
221477_s_at 1.1698 0.0232 SOD2 superoxide dismutase 2, 
mitochondria l(SOD2) 
225252_at 1.0819 0.0056 SRXN1 sulfiredoxin 1 (SRXN1) 
208948_s_at 1.1438 0.0438 STAU1 staufen double-stranded RNA 
binding protein 1 (STAU1) 
218499_at 1.6223 0.0434 STK26 serine/threonine protein kinase 26 
(STK26) 
1552798_a_at -1.8891 0.0065 TLR4 toll like receptor 4 (TLR4) 
207113_s_at 3.9122 0.0017 TNF tumor necrosis factor (TNF) 
202644_s_at 2.7125 0.0015 TNFAIP3 TNF alpha induced protein 3 
(TNFAIP3) 
201746_at 1.7735 0.0169 TP53 tumor protein p53 (TP53) 
201391_at 1.1342 0.0264 TRAP1 TNF receptor associated protein 
1(TRAP1) 
221906_at 2.9456 0.0206 TXNRD3 thioredoxin reductase 3 (TXNRD3) 
59631_at 2.5450 0.0064 TXNRD3 thioredoxin reductase 3 (TXNRD3) 
1558549_s_at -4.5040 0.0015 VNN1 vanin 1 (VNN1) 
205844_at -3.9550 0.0063 VNN1 vanin 1 (VNN1) 
205126_at 1.1141 0.0220 VRK2 vaccinia related kinase 2 (VRK2) 
205672_at 1.3707 0.0176 XPA XPA, DNA damage recognition and 
repair facto r(XPA) 
     
COPD 
Affy probe ID logFC q value Name Gene Name 
1556583_a_at -1.1444 0.0399 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
201848_s_at 1.8162 0.0366 BNIP3 BCL2 interacting protein 3 (BNIP3) 
221768_at -1.4014 0.0254 SFPQ splicing factor proline and glutamine 
rich (SFPQ) 
241752_at -1.0278 0.0319 SLC8A1 solute carrier family 8 member A1 
(SLC8A1) 
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Table E5 Nrf2 gene probes differentially regulated by infection in healthy AM 
 
Healthy 
Affy probe 
ID 
logFC q value Name Gene name 
205890_s_at 7.4702 0.0006 GABBR1 gamma-aminobutyric acid type B receptor 
subunit 1(GABBR1) 
202922_at 1.2872 0.0040 GCLC glutamate-cysteine ligase catalytic 
subunit(GCLC) 
202923_s_at 1.2349 0.0027 GCLC glutamate-cysteine ligase catalytic 
subunit(GCLC) 
213170_at 2.3971 0.0275 GPX7 glutathione peroxidase 7(GPX7) 
201415_at 0.8484 0.0322 GSS glutathione synthetase(GSS) 
209531_at 1.5210 0.0255 GSTZ1 glutathione S-transferase zeta 1(GSTZ1) 
201468_s_at 0.7719 0.0249 NQO1 NAD(P)H quinone dehydrogenase 1(NQO1) 
217678_at 4.4084 0.0092 SLC7A11 solute carrier family 7 member 
11(SLC7A11) 
209921_at 3.3825 0.0026 SLC7A11 solute carrier family 7 member 
11(SLC7A11) 
200642_at 1.1138 0.0033 SOD1 superoxide dismutase 1, soluble(SOD1) 
209077_at 0.8171 0.0303 TXN2 thioredoxin 2(TXN2) 
 
COPD 
Affy probe 
ID 
logFC q value Name Gene name 
209213_at 0.7155 0.0626 CBR1 carbonyl reductase 1 (CBR1) 
205890_s_at 0.0068 0.6882 GABBR1 gamma-aminobutyric acid type B receptor 
subunit 1 (GABBR1) 
1555330_at -0.6511 0.2319 GCLC glutamate-cysteine ligase catalytic subunit 
(GCLC) 
213170_at -0.0063 0.6882 GPX7 glutathione peroxidase 7 (GPX7) 
211630_s_at 0.2954 0.1261 GSS glutathione synthetase (GSS) 
209531_at -0.1778 0.4997 GSTZ1 glutathione S-transferase zeta 1 (GSTZ1) 
210519_s_at 0.5614 0.0899 NQO1 
NAD(P)H quinone dehydrogenase 1 
(NQO1) 
207528_s_at -0.0246 0.6882 SLC7A11 
solute carrier family 7 member 11 
(SLC7A11) 
200642_at 0.1960 0.2304 SOD1 superoxide dismutase 1, soluble (SOD1) 
209078_s_at 0.3125 0.1632 TXN2 thioredoxin 2 (TXN2) 
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    Table E6  
 
Demographics for additional non-COPD-MAP patients used in Figure 6 and 7. 
 
 
*One patient with assessment not performed 
 
  
 Healthy Non-
Smoker 
Healthy Smoker 
 
COPD 
 
N 3 1 7 
Age (years)                 62 (49-69) 55 64(47-72) 
Gender 1♀ : 2♂ 1♂ 3♀ : 4♂ 
FEV1 Litres 2.69 (1.7-3.29) 3.39 1.89 (1.21-3.77) 
FEV1 %  91.98 (86.81-100.33) 94.43 70.8 (48.69-113) 
FVC litres  3.56 (2.37-4.49) 4.58 3.3 (1.32-5.28) 
GOLD Stage * N/A N/A 2 GOLD A 
4 GOLD B 
0 GOLD C 
0 GOLD D 
Non-Frequent 
/Frequent 
N/A N/A NF 5 (0 Exacerbations = 
3, 1 Exacerbation = 2 
 F 2 (2 Exacerbations =1, 
3 Exacerbations =1, >3 
Exacerbations =0) 
Pack Years                  N/A 22.6 36.5 (23.2-55) 
Smoking Status: 
Current/Ex/Never 
0/0/3                    1/0/0 4/3/0 
 
 
Inhaled Corticosteroids 
use 
0 0  4 
 
Vaccine 2 Yes, 1 No N/A 5 Yes, 2 No 
St George's 
Respiratory 
Questionnaire 
(SGRQ) Total score * 
N/A N/A 31.97 (4.92-70.28) 
COPD Assessment 
Test (CAT) * 
N/A N/A 16.7 (7-30) 
6 Minute Walk (m) N/A N/A N/A 
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Figure E1. Relationship between bacterial uptake and exacerbation frequency. Alveolar macrophages (AM) 
were collected from patients with COPD and were challenged with non-opsonized (NO) or opsonized (O) 
serotype 14 S. pneumoniae for 4 h, before extracellular bacteria were killed by the addition of antibiotics. At 
the designated time post-antibiotics, viable bacteria in duplicate wells were measured and plotted against 
exacerbation frequency. 'n' values for NO/O by exacerbation frequency; 0=20/15, 1=7/4, 
2=3/2,3=7/74=3/3,5=2/1.  
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Figure E2.  COPD Macrophages show no defect in early-phase bacterial killing.   (A-D) Alveolar macrophages 
(AM) (A and B) or monocyte derived macrophages (MDM) were collected from patients with COPD (A and C) 
or healthy donors (B and D) and were challenged with non-opsonized or opsonized serotype 14 S. 
pneumoniae for 4h, before extracellular bacteria were killed by the addition of antibiotics. At the designated 
time post-antibiotics, viable bacteria in duplicate wells were measured, n=3, no significant differences 
between any groups.  
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Figure E3.  COPD alveolar macrophages show defects in uptake of opsonized S. pneumoniae. Alveolar 
macrophages (AM) or monocyte derived macrophages (MDM) were collected from patients with COPD or 
healthy donors and were challenged with non-opsonized or opsonized serotype 14 S. pneumoniae for 
4h,  before performing fluorescence microscopy to determine adherent (green, continuous arrows) and 
internalized bacteria (blue, broken arrows. Representative images are  shown for fluorescence microscopy of 
AM (A)  and MDM (B) with binding shown in the upper row and internalization in the lower row. In these 
experiments incubation on ice was a positive control for binding, IgG1 treatment to block Fc R was a 
negative control for both binding and internalization and treatment with 20% immune serum was a positive 
control for internalization. Pictures are representative of three donors in each condition. (C-F) AM (C and E) 
and MDM (D and F) from healthy and COPD donors (non-frequent or frequent exacerbators) were analyzed 
to record bacterial binding and internalization under the same conditions by fluorescence microscopy, n=4. * 
p<0.05 by One-way ANOVA.  
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Figure E4. COPD Macrophages show no defect in Fc-gamma expression or expression of EPAC-1 RAP-1 and 
RAC-1.    
(A-B) Healthy and COPD alveolar macrophages (AM) AM (A) and monocyte derived macrophages (MDM) (B) 
were analyzed for the expression of either CD16, CD32 or CD64 by flow cytometry, n=3, no significant 
differences between healthy or COPD. (C-D) Healthy or COPD AM from two individual donors (i and ii) were 
either mock-infected (Spn-) or challenged with serotype 14 S. pneumoniae (Spn +). 4h post-challenge cells 
were lysed and the expression of EPAC-1, RAP1 and RAC1 assessed by western blot. The blot is 
representative of one of three. (C) Positive controls (+) for EPAC-1, RAP-1  and RAC-1 were  hypoxic MDM 
(as compared to nomoxic MDM (-)).  
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Figure E5 Pneumococcal antibodies are detectable in broncholaveolar lavage fluid. Bronchoalveolar lavage 
fluid from 13 healthy and 16 COPD patients was analyzed by multiplex immunoassay for presence of 
pneumococcal antibodies against 13 S. pneumoniae serotypes.  
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Figure E6. Transcriptional response of AM reveals less differential gene expression in COPD in response to 
infection.  Ontology analysis of Healthy and COPD networks following pneumococcal challenge. The 
overrepresented terms (calculated with BiNGO software in Cytoscape, FDR <0.05, Hypergeometric 
clustering) are visualised. The terms for Cellular Response to Stress are highlighted by an arrow in each 
network.  
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Figure E7. Treatment with Nrf-2 agonists does not induce apoptosis or necrosis. COPD alveolar macrophages 
were pre-treated with sulforaphane (+Sulf) or compound 7 for 16h. Cells were then assessed for either 
necrosis (A) or apoptosis (n=3).  
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Figure E8. Sulforaphane treatment does not modify Fc-gamma expression in healthy or COPD macrophages. 
Healthy or COPD alveolar macrophages (AM)(A) or monocyte-derived macrophages (MDM)(B) were pre-
treated with sulforaphane (+Sulf) for 16h. Cells were then assessed for expression of CD16, CD32 or CD64 
by flow cytometry, n=3.  
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